



## Review

## Typhoid fever infection – Antibiotic resistance and vaccination strategies: A narrative review

Cristina Masuet-Aumatell<sup>a,\*</sup>, Jorge Atouguia<sup>b</sup><sup>a</sup> Preventive Medicine Department, Bellvitge Biomedical Research Institute (IDIBELL), University Hospital of Bellvitge, Faculty of Medicine, University of Barcelona, Feixa Llarga s/n, L'Hospitalet de Llobregat, 08907, Barcelona, Catalonia, Spain<sup>b</sup> Instituto Higiene e Medicina Tropical, Universidade Nova de Lisboa, Rua da Junqueira, 100, Lisbon, Portugal

## ARTICLE INFO

## Keywords:

*Salmonella typhi*  
Risk  
Travel  
Drug resistance  
Bacterial  
Typhoid-paratyphoid vaccines

## ABSTRACT

Typhoid fever is a bacterial infection caused by the Gram-negative bacterium *Salmonella enterica* subspecies enterica serovar Typhi (*S. Typhi*), prevalent in many low- and middle-income countries. In high-income territories, typhoid fever is predominantly travel-related, consequent to travel in typhoid-endemic regions; however, data show that the level of typhoid vaccination in travellers is low. Successful management of typhoid fever using antibiotics is becoming increasingly difficult due to drug resistance; emerging resistance has spread geographically due to factors such as increasing travel connectivity, affecting those in endemic regions and travellers alike.

This review provides an overview of: the epidemiology and diagnosis of typhoid fever; the emergence of drug-resistant typhoid strains in the endemic setting; drug resistance observed in travellers; vaccines currently available to prevent typhoid fever; vaccine recommendations for people living in typhoid-endemic regions; strategies for the introduction of typhoid vaccines and stakeholders in vaccination programmes; and travel recommendations for a selection of destinations with a medium or high incidence of typhoid fever.

## 1. Introduction

Typhoid is a bacterial infection caused by the Gram-negative bacterium *Salmonella enterica* subspecies enterica serovar Typhi (*S. Typhi*). Typhoid fever is usually contracted by ingestion of food or water contaminated by faecal or urinary carriers excreting *S. Typhi* [1]. The predominant symptom of infection is high fever, with other symptoms including nausea, abdominal pain and abnormal bowel movements [2]. Once prevalent worldwide, improvements in the provision of clean water and sewerage systems has led to a dramatic decrease in the incidence of typhoid fever with the burden of disease now predominantly residing in low- and middle-income countries where sanitary conditions may be poor [1].

In developed countries, typhoid fever is a predominantly travel-associated disease [3], impacting travelling populations such as tourists, military personnel, temporary workers, or travellers visiting friends

or relatives (VFR) in endemic areas, with risk varying by the geographical region visited [3–6], the duration of travel, integration with local cultures, traveller concurrent diseases or medications.

Successful management of typhoid fever using antibiotics is becoming increasingly difficult due to drug resistance [7,8]; emerging resistance has spread geographically due to factors such as increasing travel connectivity, affecting those in endemic regions and travellers alike.

The aim of this article is to provide an overview of: the epidemiology and diagnosis of typhoid fever; the emergence of drug-resistant typhoid strains in the endemic setting; drug resistance observed in travellers; vaccines currently available to prevent typhoid fever; vaccine recommendations for people living in typhoid-endemic regions; strategies for the introduction of typhoid vaccines and stakeholders in vaccination programmes; and travel recommendations for a selection of destinations with a medium or high incidence of typhoid fever.

**Abbreviations:** AE, adverse event; CI, confidence interval; Ig, immunoglobulin; MDR, multidrug resistance/resistant; PCR, polymerase chain reaction; *S. Typhi*, *Salmonella enterica* subspecies enterica serovar Typhi; TCV, typhoid conjugate vaccine; TMP-SMX, trimethoprim-sulfamethoxazole; UDP, uridine-diphosphate; VFR, travellers visiting friends or relatives; Vi-CRM<sub>197</sub>, Vi polysaccharide conjugated with CRM<sub>197</sub>; Vi-DT, Vi polysaccharide conjugated to diphtheria toxoid; ViPS, Vi polysaccharide; Vi-rEPA, Vi polysaccharide bound to the recombinant exoprotein of *Pseudomonas aeruginosa*; XDR, extremely drug resistant; WHO, World Health Organization.

\* Corresponding author.

E-mail addresses: [cmasuet@bellvitgehospital.cat](mailto:cmasuet@bellvitgehospital.cat) (C. Masuet-Aumatell), [j.atouguia@gmail.com](mailto:j.atouguia@gmail.com) (J. Atouguia).

<https://doi.org/10.1016/j.tmaid.2020.101946>

Received 13 November 2019; Received in revised form 1 December 2020; Accepted 3 December 2020

Available online 8 December 2020

1477-8939/© 2021 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

## 2. Methodology


An original literature search was conducted on March 19, 2019 in PubMed and EmBase, limited to English-language articles and studies of human individuals. The search terms were ‘Typhoid [Title] AND resistan\* [Title]’, limited to the last 15 years, and ‘Typhoid [Title] AND vaccin\* [Title/Abstract] AND resistan\* [Title/Abstract]’, limited to the last 20 years. Reference lists of relevant articles were also screened to identify other additional sources. Apart from abstracts listed in EMBASE, grey literature (e.g. government resources and congress publications) was not included, and duplicate articles were removed. The search results were screened by a non-blinded reviewer to exclude articles that did not provide information about typhoid in humans. Possible articles of interest were retrieved, reviewed and relevant data extracted. Dual validation was not performed as the intention was not to provide a quantitative meta-analysis. Owing to the time since the original search was run, the literature included in this review was updated in the week commencing November 16, 2020 and relevant additional literature added.

## 3. Overview of the epidemiology of typhoid fever

An estimated 26.9 million episodes of typhoid fever occur annually worldwide (interquartile range 18.3–35.7 million) [9], although precise estimates are difficult to establish. This is due to the non-specific presenting symptoms and signs, under-reporting of cases (screening procedures are not undertaken if the patient is asymptomatic), and lack of

suitable diagnostics in many regions (see section 3.1 “Diagnosis of typhoid fever”). The highest burden of typhoid fever is thought to be on the Indian subcontinent, however there is considerable heterogeneity in the distribution of typhoid fever [10]. In sub-Saharan Africa, the incidence of typhoid has historically been poorly described [11]. Indeed, data from the Typhoid Surveillance in Africa Program and other groups have shown that the incidence in African regions may be as high as (or exceed) that in Asia [12–14], affecting both rural and urban populations [14,15].

At the regional level, modelling data from Antillon and colleagues estimate that the incidence of typhoid fever in the Eastern sub-Saharan Africa region could be 620 cases per 100,000 person-years (95% confidence interval [CI] 213–2921), approximately three-fold higher than the Southeast Asia region (217 cases per 100,000 person-years; 95% CI 88–571) [13]. An analysis by the GBD 2017 Typhoid and Paratyphoid Collaborators estimated that, in 2017, South Asia had the highest age-standardised incidence rate (549 [481–625] cases per 100,000 person-years) and the largest number of cases (10.3 million [9.0–11.7]), accounting for 71.8% of global cases, while the sub-Saharan Africa region accounted for 12.1% (1.73 million [1.45–2.06]) of global cases (Fig. 1) [16]. A multicentre population-based prospective study across 13 sites in 10 African countries highlighted that children aged 2–14 bear the greatest burden of typhoid fever [17]. The degree of uncertainty is considerable in regions where typhoid surveillance is weak or non-existent [13], emphasising the importance of capturing wide-ranging surveillance data to fully understand typhoid incidence and the likely outcome of different interventions.



**Fig. 1.** Incidence rates (per 100,000) of typhoid and paratyphoid fevers, by country, in 2017. Reproduced with permission, Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license [16].

Along with paratyphoid fever (caused by *Salmonella enterica* subspecies serovar Paratyphi A, Paratyphi B and Paratyphi C), typhoid fever is a type of enteric fever [18]. *S. Typhi* is estimated to cause 76.3% (95% CI 71.8–80.5) of cases of enteric fever globally in 2017, with an estimated mean all-age global case fatality of 0.95% (95% CI 0.54–1.53), with higher fatality among children and older adults, and among those living in low income countries [16].

During the course of infection, carriage can be split into three periods – convalescence, temporary and chronic [19]. As many as 10% of convalescent carriers shed bacilli in faeces for up to 3 months post-infection [1]. Following resolution of the disease, approximately 1–4% of typhoid patients progress to the carrier state, excreting the bacilli for more than 1 year [1]. Typhoid fever-causing *Salmonella* have no known environmental reservoir, but it is thought that the chronic asymptomatic carrier is responsible for continued maintenance of the bacteria within human populations [19]. The carrier state has not been extensively studied as the majority of chronic carriers in endemic settings are asymptomatic [1] and a substantial proportion may have had no clinical history of typhoid [19]. However, it is known that chronic carriage is more common in women and increases with age [20]. It is likely that breach of the intestinal epithelial barrier, evasion of early innate immune-mediated killing, and localisation to the biliary tract and gallbladder are requirements for development of the carrier state [19]. Approximately 90% of carriers present with gallstones [21]. Mechanistic studies have shown that *S. Typhi* forms biofilms on gallstones [22], the formation of which is proposed to aid in their survival and persistence during this phase of the transmission cycle [23].

Recent outbreaks, such as the ongoing outbreak in Zimbabwe (active since 2017), demonstrate how poor sanitation and overcrowding are drivers of seasonal outbreaks of typhoid fever and other waterborne diseases [24]. In addition to water-related and socio-economic risks, improper food handling is a risk factor [25,26], underlying the importance of detecting index cases to allow education (and vaccine strategies) to be appropriately targeted.

Typhoid fever is extremely uncommon in countries that have access to treated water supplies and sanitation systems that remove human waste [27]. In non-endemic regions, typhoid is a predominantly travel-associated disease [28–33]. In 2016, 22 countries from the EU reported over 1100 cases (typhoid and paratyphoid combined), with France, Italy and the UK accounting for approximately 70% of those cases [33]. Of those with available information, 82.5% were travel-related, with India and Pakistan accounting for the majority of cases [33]. In the USA, 79% (240/303) of typhoid fever patients travelled or lived outside of the country in the 30 days prior to illness [31]. Previously it was estimated that the incidence of typhoid among travellers to a selection of low- and middle-income countries was  $\leq 1$  case per 100,000 travellers, except for those who visited Nepal or India where the case rate was 7.9 or 27–81 cases per 100,000 travellers, respectively [3]. The most common reason to travel abroad for patients who subsequently contracted typhoid fever was to visit friends or relatives [29,31,33]. The literature suggests that VFR are at higher risk of contracting travel-related illness, compared with other groups of travellers, due to factors including an increased likelihood of travelling for longer periods of time, travel to rural destinations and being more likely to drink untreated water [34]. Additionally, as VFR may co-habit with their friends and family, they may have greater exposure to asymptomatic carriers in the endemic population (and possibly experience lower levels of sanitation in the home setting), contributing to their increased risk of typhoid fever compared with other travellers.

Another group of travellers potentially at risk of typhoid are military personnel deployed to typhoid-endemic regions. A review of the typhoid fever cases reported in the US military (1998–2011) revealed 205 cases of typhoid fever among military service members, for an incidence of 1.09 per 100,000 person-years, consistent with the incidence of typhoid in the general US population during that same time period, the majority of which was travel-related [35]. Increases in deployment of military

personnel to countries with medium or high incidence estimates could be expected to increase the risk of typhoid fever, however this has not been shown, in part due to deployed troops not experiencing the living conditions of the local population [35].

The risk of acquiring typhoid increases with the duration of stay. Correspondingly, in a study of travellers from Greece to typhoid-endemic areas (such as sub-Saharan Africa and Southeast Asia), it was shown that typhoid vaccine administration is statistically associated with the duration of stay [36] as travellers look to mitigate their risks. Approximately 20% of travellers who stayed <1 month underwent vaccination compared with nearly 35% who stayed  $\geq 6$  months [36]. However, data show that typhoid fever is a risk even for short-term travel – 5% (31/626) of travellers from the USA with typhoid fever reported that their travel outside of the USA lasted  $\leq 1$  week compared with 60% (376/626) whose travel lasted  $\leq 6$  weeks [37]. Therefore, behaviours and expected exposure to typhoid fever at the destination should be considered, not only the length of travel.

Travellers who acquire typhoid fever are rarely immunised. Previous data of travellers who developed typhoid fever show that just 4% (36/1027) reported having received a typhoid vaccination at any point during the previous 5 years preceding travel [37]. Data from the US military revealed that 26% (53/205) of military personnel had a documented *S. Typhi* vaccination within 2 years of typhoid fever diagnosis [35]. More recent data of young Canadian travellers with typhoid fever revealed that 0% (0/39) had a record of typhoid vaccination [30]. This low rate of vaccination is therefore one of the key factors that contribute to the occurrence of typhoid infection in travellers [30,37].

### 3.1. Diagnosis of typhoid fever

Isolation of *S. Typhi* from blood is the current gold standard for determining typhoid fever infection [38]. Bacterial culture from bone marrow is more sensitive but is difficult to obtain, invasive and is impractical for routine use [38]. Although blood cultures remain the gold standard for diagnosis, this method has poor sensitivity [38]. In addition, culturing takes at least 48 h to generate results, and optimal usage is hampered by lack of healthcare infrastructure and adequately trained laboratory personnel in resource-limited countries where typhoid fever is common [38,39].

The Widal test is a serological test that detects agglutinating antibodies against the O and H antigens [38]. It is widely used due to its simplicity and low cost [38] but has low sensitivity [40] and is highly operator dependent [41], with values varying considerably between geographical areas [1]. In addition, the background level of antibodies in a normal healthy population within a typhoid-endemic region means that proper interpretation of the Widal test results entails collection of sera from two visits (spaced 10–14 days apart) and requires each country to determine the appropriate antibody titre with which to diagnose typhoid [39,42], since there is no universal titre cutoff to define the disease. With the emergence of antibiotic resistance (see Section 4, “Overview of the treatment of typhoid fever and the emergence of drug-resistant typhoid strains”), the Widal test is inadequate as it does not provide susceptibility results [43].

Nucleic acid amplification tests, including conventional polymerase chain reaction (PCR), nested, multiplex and real-time PCR, have been developed for the detection of *S. Typhi* DNA in blood [39]. The main challenges preventing widespread use in low-resource settings are the high costs associated with this technology [39].

There are several commercially available typhoid rapid antibody tests that can generate results in as little as 2 min [44] allowing prompt treatment with antimicrobials for those with a positive result. One qualitative test, Typhidot®, uses pre-dotted antigen strips to detect the presence of immunoglobulin (Ig)M and -G antibodies to an outer membrane protein [44]. A semi-quantitative colourimetric test (IDL TUBEX® TF) relies on visual and subjective examination of colour reactions to detect *anti*-O:9 antibody titres [44]. However, in comparative

studies of performance utilising blood culture as the comparator, this type of testing can perform poorly [44]. A recent meta-analysis reported an average sensitivity of 78% (95% CI 71–85; the ability to identify true positives) and specificity of 87% (95% CI 82–91; the ability to identify true negatives) for TUBEX [38]. Analysis of all Typhidot variants as a group showed an average sensitivity of 84% (95% CI 73–91) and specificity of 79% (95% CI 70–87) [38]. A recent study conducted in Bangladeshi patients revealed that the sensitivity of typhoid rapid antibody tests may be as low 60.2% (95% CI 49.3–71.2) and 59.6% (95% CI 50.1–69.3), respectively [45]. These results emphasise the difficulties of laboratory diagnosis of typhoid.

At present there is no gold standard for the detection of chronic typhoid carriers. Standard practice has been to detect typhoid carriage through serial analysis of stool and urine samples (using culturing), however this is logistically challenging and suffers from low sensitivity [19].

The presenting signs and symptoms of typhoid fever are shared with other febrile illnesses (such as malaria, dengue or other arbovirus fevers) [46], and thus differentiating *S. Typhi* infection from other sources of fever in endemic areas is a diagnostic challenge [38]. In most endemic areas (at least in Africa), the only means for diagnosis of a febrile patient is the Widal test for typhoid fever or the thick blood smear for malaria and, as has been shown, the Widal test performs poorly. The lack of diagnosis (because tests are not ordered), misdiagnosis (due to the use of insensitive methods), poor surveillance and inadequate healthcare infrastructure are common problems in resource-limited settings. New strategies that are specific, sensitive, scaleable and cost-effective are required to correctly identify both acute sufferers and chronic carriers of typhoid, in order to stop expansion of the disease and determine the real global burden of *S. Typhi*.

For patients in countries where typhoid is not endemic, determination of the patient's travel history is crucial [1].

#### 4. Overview of the treatment of typhoid fever and the emergence of drug-resistant typhoid strains

The treatment of typhoid fever normally consists of antibiotics [1, 11]; early initiation of effective antimicrobial therapy has been shown to shorten the duration of the illness and reduce the risk of complications and death [47]. Because of the high risk of morbidity and mortality if left untreated [48], clinicians may administer antibiotics to patients in the absence of a confirmed diagnosis (on the clinical suspicion of typhoid fever). However, large surveillance studies from Asia and Africa indicate that only 1–4% of people with suspected typhoid actually have

culture-confirmed typhoid [49], which suggests that there might often be substantial overtreatment with unnecessary antibiotics.

One of the effects of empiric prescribing of antimicrobials has been an increase in selective pressure on *S. Typhi* [49,50]. Since 1948, when the efficacy of chloramphenicol to treat typhoid was discovered, there has been a pattern of antibiotic usage and resultant development of resistance to antimicrobial therapies [7]. Subsequently, antimicrobial resistance has become a major threat to the treatment of typhoid with increasing levels of treatment failure [7,8] (Fig. 2).

Multidrug resistance (MDR) is historically used to describe combined resistance to the first-line antibiotics chloramphenicol, co-trimoxazole (trimethoprim-sulfamethoxazole) and ampicillin [2]. *S. Typhi* can harbour complex MDR elements, either on self-transmissible plasmids carrying a cassette of antimicrobial resistance genes [51], or integrated into the chromosome (which is more common than previously thought) [52]. While antibiotic selection maintains resistance genes on the plasmid, there also appears to be competition between plasmids encoding the same resistance phenotype [53].

MDR *S. Typhi* is now considered endemic in many developing countries, especially in areas of South and Southeast Asia [2], mediated by the dissemination of the specific H58 lineage across Asian and African countries [8]. As with the disease incidence, antimicrobial agent susceptibility patterns vary geographically [54]. High incidences of MDR *S. Typhi* are found in areas with a high burden of typhoid, particularly in children aged under 15 years [55]. There is a paucity of data on the geographical distribution, incidence and phylogenetics of MDR *S. Typhi* in sub-Saharan Africa [55], however the H58 clade of *S. Typhi* is associated with the MDR phenotype [56] and with much of the typhoid occurring in the last decade in East and Southern Africa [54].

Longitudinal studies show that the proportion of MDR strains decrease over time as clinicians respond to resistance and use alternative drugs [57]. Correspondingly, MDR *S. Typhi* is on the decline in South and Southeast Asia, because of the reduced usage of these first-line drugs in this region [54].

In response to the development and spread of MDR *S. Typhi*, the use of fluoroquinolones, (ciprofloxacin, ofloxacin, fleroxacin and pefloxacin) became widely accepted as an alternative to treat typhoid fever [2]. However reports of decreased susceptibility to fluoroquinolone soon followed both in endemic areas and in travellers returning from such areas [2]. In areas with a high prevalence of both MDR and fluoroquinolone resistance, azithromycin (an azalide antimicrobial) and extended-spectrum cephalosporins (e.g. ceftriaxone) tend to be used for treatment [2].

The first outbreak of an extremely drug resistant (XDR) H58 clone




Fig. 2. History of antibiotic efficacy studies and the emergence of antimicrobial resistance in *Salmonella typhi*. Abbreviations: MDR; multidrug resistant; TMP-SMX, trimethoprim-sulfamethoxazole. Strains noted to be “nonsusceptible” are intermediately or fully resistant. Reproduced with permission, copyright © 2018 Andrews et al. [7].



harbouring resistance to not only the three first-line drugs (chloramphenicol, co-trimoxazole and ampicillin), but also fluoroquinolones, and extended-spectrum cephalosporins, began in Sindh province, Pakistan in 2016 [43,58,59]. All of the XDR isolates belonged to the H58 clade and it is thought that the plasmid conferring resistance originated in *Escherichia coli* and was acquired by an MDR H58-endemic *S. Typhi* clone in Pakistan [43]. This outbreak resulted in 5372 XDR *S. Typhi* cases reported from 2016 to 2018 [60]. First reported in June 2019, several areas of Sindh province are again suffering from an outbreak of typhoid, with two child deaths and illness in more than 150 people already recorded. Thus far, five of 51 typhoid cases have been reported as XDR, with results of several other cases awaiting. Health authorities are planning to launch a mass vaccination drive to gain control of this current outbreak [61]. Where patients experience resistance to all first- and second-line drugs, the carbapenems (e.g. imipenem, meropenem and ertapenem) and tigecycline are considered potential alternatives [2].

In addition to the difficulties of ensuring patients receive effective treatment, there are also cost implications associated with resistance: the cost of therapy for resistant cases can be approximately 70% greater than the cost of sensitive typhoid cases, driven mostly by an increase in physician and nursing care [62]. Even with appropriate treatment, the risk of relapse remains, with approximately 5–10% of immunocompetent patients relapsing [63]. Typhoid relapse cases have been reported in typhoid-endemic countries and in travellers returning from those regions [48,63,64]. In one small study from India, patients with drug-resistant typhoid who initially received ineffective therapy had a higher relapse rate following effective treatment compared with those infected with pan-sensitive strains [63].

For the treatment of chronic carriers, eradication has been achieved with some success using ampicillin or amoxicillin, sometimes combined with probenecid or co-trimoxazole (dependent upon the susceptibility of the strain) [2]. A small study of 12 chronic *S. Typhi* carriers revealed a 92% cure rate with a 4-week regimen of fluoroquinolones (ciprofloxacin orally twice a day for 28 days) [65]. At present, there are few data on this subgroup and more research is necessary to determine the best approach for treatment.

#### 4.1. Drug-resistance in travellers

Resistance to antibiotics has been observed in travellers from non-endemic regions with typhoid fever, with patterns reflecting the conditions in typhoid-endemic countries. Case reports of travellers returning to Spain from Guatemala [66], and to Germany from Iraq [67], have documented infections of an extended-spectrum beta lactamase-producing *S. Typhi* strain.

Data gathered in the USA from the National Typhoid and Paratyphoid Fever Surveillance System and National Antibiotic Resistance Monitoring System revealed that antimicrobial resistance was common [68]. Among *S. Typhi* isolates, 314 (29%) were susceptible to all clinically relevant antimicrobial agents, 750 (69%) were resistant to nalidixic acid or had decreased susceptibility to ciprofloxacin, 127 (12%) were MDR, and 108 (10%) were both nalidixic acid resistant/decreased susceptibility to ciprofloxacin and MDR [68]. Isolates resistant to nalidixic acid (a synthetic quinolone that is a marker of decreased susceptibility or resistance to fluoroquinolones) originated mainly in southern Asia whilst MDR cases originated from southern Asia and Africa [68].

The afore-mentioned typhoid fever outbreak of 2016–2018 in Sindh province resulted in five travel-related cases in children visiting relatives in Pakistan and returning to the USA [69], and one in the UK [43]. In April 2019, a ceftriaxone-resistant *S. Typhi* case was detected in a pregnant woman returning to Denmark from a family visit to Sindh province [70]. In August 2019, the first case of XDR typhoid was reported in Australia [71].

Collectively, the occurrence of resistant cases necessitates heightened vigilance and re-consideration of treatment strategies for those

who have visited a region that has high levels of antimicrobial resistance. *S. Typhi* is quickly able to acquire new resistance mechanisms. As long-distance travel becomes more accessible and migration between endemic and non-endemic regions increases, access to information regarding local and regional susceptibility is important to guide empirical treatment [10]. Consequently, the landscape of resistance is dynamic. The World Health Organization (WHO) has recommended that the surveillance of typhoid fever be strengthened, including surveillance to monitor known resistance, detect new and emerging resistance, and mitigate its spread [72].

## 5. Vaccines available for typhoid

To stop the expansion of typhoid, interventions should mostly focus on prevention. Along with improvements in antibiotic stewardship, public sanitation, availability of clean drinking water, safe food handling practices and public health education, vaccination in endemic areas is one strategy to prevent typhoid fever. The WHO recommends programmatic use of typhoid vaccines for the control of typhoid fever [73].

Two typhoid vaccines are widely available – Vivotif® (Emergent BioSolutions), an enteric-coated capsule formation of the live attenuated Ty21a vaccine, and TYPHIM Vi® (Sanofi Pasteur), a liquid formulation of the unconjugated Vi polysaccharide (ViPS) vaccine [74,75]. Other vaccines available include the combination typhoid-hepatitis A vaccine VIVAXIM® (Sanofi Pasteur) [76]. There are also two newer generation ViPS-tetanus toxoid conjugate vaccines (typhoid conjugate vaccines [TCVs]) currently licensed, Typbar-TCV™ (Bharat Biotech) and Ped-aTyph™ (Bio-Med) [77,78]. Selected vaccines are summarised in Table 1.

### 5.1. Ty21a vaccine

The Ty21a vaccine was developed by chemical-induced mutagenesis of the *S. Typhi* Ty21 strain, resulting in a *galE* mutant and the inability to express the Vi polysaccharide antigen [109]. Inactivation of the *galE* gene generates a lack of uridine-diphosphate (UDP)-galactose-4-epimerase [110], which is responsible for the conversion of UDP glucose into UDP galactose. Consequently, there is intracellular accumulation of galactose derivatives and subsequent bacterial lysis, thus eliminating virulence of the vaccine strain [110,111]. Lipopolysaccharide synthesis is preserved [109].

*S. Typhi* is an intracellular bacterium and thus needs T cell-dependent immunological response for resolution [112]. Vaccination with Ty21a activates a broad immune response, with both humoral and systemic cell-mediated immune responses. The serum antibody response to Ty21a is a rise in serum IgG antibody against the O polysaccharide of *S. Typhi* [113]. Data have shown that the rate of seroconversion of IgG anti-O antibodies increases as more doses are administered within a period of 7 days [88] and that the humoral response is dose-dependent [114].

Following oral immunisation, mucosal antibody responses have been reported. Vaccination studies in healthy adult volunteers have revealed that oral Ty21a immunisation results in an increase in the concentration of IgG anti-lipopolysaccharide [115,116] as well as an increase in levels of faecal IgA (total and/or specific) [115–117]. Data have also shown that after oral vaccination antibody-secreting cells that produce specific IgA to *S. Typhi* O-polysaccharide bear homing receptors which commit them to migrate to the intestinal mucosa [118]. Cell-mediated responses include contributions from CD4<sup>+</sup> helper T cells and CD8<sup>+</sup> cytotoxic T cells [27].

In the late 1980s–1990s, a series of large-scale randomised, double-blind, controlled field trials (pre-licensure) of Ty21a efficacy were conducted assessing different dosage regimens (single or multiple doses), dosing intervals and formulations. The evidence from the trials that assessed the dosing regimen currently recommended for the Ty21a

**Table 1**  
Typhoid vaccines [74,75,77–103].

Brand and manufacturer	Vivotif® Emergent BioSolutions	TYPHIM Vi® Sanofi Pasteur	Typbar-TCV™ Bharat Biotech	PedaTyph™ Bio-Med
Formulation Type	<ul style="list-style-type: none"> <li>• Enteric-coated capsules [74]</li> <li>• Live attenuated Ty21a strain of S. Typhi [74]</li> </ul>	<ul style="list-style-type: none"> <li>• Liquid [75]</li> <li>• Purified Vi capsular polysaccharide from the Ty2 S. Typhi strain [75]</li> </ul>	<ul style="list-style-type: none"> <li>• Liquid [77]</li> <li>• Vi polysaccharide conjugated with nontoxic tetanus toxoid carrier protein [77]</li> </ul>	<ul style="list-style-type: none"> <li>• Liquid [78]</li> <li>• Purified Vi capsular polysaccharide from the Ty2 S. Typhi strain conjugated with nontoxic tetanus toxoid protein [78]</li> </ul>
Route of administration	<ul style="list-style-type: none"> <li>• Oral [74]</li> </ul>	<ul style="list-style-type: none"> <li>• Injectable</li> </ul>	<ul style="list-style-type: none"> <li>• Injectable</li> </ul>	<ul style="list-style-type: none"> <li>• Injectable</li> </ul>
Recommended dose/regimen	<ul style="list-style-type: none"> <li>• Three dose regimen, taken on alternate days [74]</li> <li>• Four dose regimen in USA and Canada [79]<sup>a</sup></li> <li>• Entire vaccination schedule to be completed at least one week prior to travel to endemic area [74]</li> </ul>	<ul style="list-style-type: none"> <li>• Intramuscular [75]</li> <li>• One dose [75]</li> <li>• Optimum antibody protection may be reached 2 weeks after administration [75]</li> </ul>	<ul style="list-style-type: none"> <li>• Intramuscular [77]</li> <li>• One dose [77]</li> <li>• Prevention is effective 2–3 weeks after immunisation [77]</li> </ul>	<ul style="list-style-type: none"> <li>• Intramuscular [78]</li> <li>• One dose [78]</li> <li>• Prevention becomes effective 4 weeks after immunisation [78]</li> </ul>
Efficacy of recommended dose regimen	<p><b>Randomised, double-blind placebo-controlled field study [80,101]</b></p> <p>Vivotif vaccination arm: n = 22,170 school-children, aged 6–21, three doses.</p> <ul style="list-style-type: none"> <li>• Year 1: 71% (95% CI 35–87)</li> <li>• Year 2: 61% (95% CI 12–82)</li> <li>• Year 3: 67% (95% CI 47–79)</li> <li>• Total years 1–3: 67% (95% CI 47–79)</li> </ul> <p><b>Additional follow-up</b></p> <ul style="list-style-type: none"> <li>• Years 1–7: 62% (95% CI 48–73)</li> <li>• Years 4–7: 61% (95% CI 34–73)</li> </ul> <p><b>Randomised, double-blind placebo-controlled field study [87].<sup>b</sup></b></p> <p>Vivotif vaccination arms: n = 34,696 school children, aged 5–19, three doses</p> <ul style="list-style-type: none"> <li>• Year 3: 33.2% (95% CI 0–57)</li> </ul>	<p><b>Randomised, double-blind placebo-controlled field study [82]</b>. TYPHIM Vi vaccination arm: n = 3457 individuals, aged 5–44</p> <ul style="list-style-type: none"> <li>• 17 months post-vaccination: 75% (95% CI unreported)</li> </ul> <p><b>Randomised, double-blind placebo-controlled field trial [83,84]</b> TYPHIM Vi vaccination arm: n = 5692 children, aged 5–15/16<sup>c</sup></p> <ul style="list-style-type: none"> <li>• Year 1: 61% (95% CI 6–82)</li> <li>• Year 2: 52% (95% CI 5–76)</li> <li>• Year 3: 50% (95% CI 0–78)</li> <li>• Total years 1–3: 55% (95% CI 30–71)</li> </ul>	<p><b>Randomised human challenge study [85]</b></p> <p>Typbar-TCV vaccination arm: n = 37 healthy adult volunteers, aged 18–60, one dose</p> <ul style="list-style-type: none"> <li>• 72 h post-challenge: 87.1% (95% CI 47.2–96.9)</li> </ul> <p><b>Randomised controlled Phase 3 trial [104]</b></p> <p>Typbar-TCV vaccination arm: 10,005 individuals, aged 9 months–16 years, one dose</p> <ul style="list-style-type: none"> <li>• Year 1: 81.6% (95% CI 58.8–91.8)</li> </ul>	<p><b>Cluster randomised field study [86]</b></p> <p>Mitra, 2015, Kolkata, India. PedaTyph vaccination arm: n = 905 school children, aged 6 months–12 years, one or two doses</p> <p><i>Two dose<sup>d</sup></i></p> <ul style="list-style-type: none"> <li>• Year 1: 100% (95% CI 97.6–99.5)</li> </ul>
Revaccination	<ul style="list-style-type: none"> <li>• 3 years following the most recent vaccination for all individuals [74]</li> </ul>	<ul style="list-style-type: none"> <li>• 3 years under conditions of repeated or continuous exposure [75]</li> </ul>	<ul style="list-style-type: none"> <li>• Booster dose may be given after 3 years [77]</li> </ul>	<ul style="list-style-type: none"> <li>• Booster dose may be given from 2.5 to 3 years [78]</li> </ul>
Indirect (herd) protection	<ul style="list-style-type: none"> <li>• Yes [88]</li> </ul>	<ul style="list-style-type: none"> <li>• Unclear<sup>e</sup></li> </ul>	<ul style="list-style-type: none"> <li>• Unknown</li> </ul>	<ul style="list-style-type: none"> <li>• Unknown</li> </ul>
Cross-protection against paratyphoid	<ul style="list-style-type: none"> <li>• Moderate protection against paratyphoid B fever (efficacy 49% 95% CI 8–73) [89]</li> </ul>	<ul style="list-style-type: none"> <li>• No [75]</li> </ul>	<ul style="list-style-type: none"> <li>• No [77]</li> </ul>	<ul style="list-style-type: none"> <li>• Unknown [78]</li> </ul>
Recommended target age for vaccination	<p><i>Highest level of recommendation: 2b</i></p> <ul style="list-style-type: none"> <li>• Indicated for use in adults and children &gt;5 years of age [74]<sup>f</sup></li> </ul>	<p><i>Highest level of recommendation: 2b</i></p> <ul style="list-style-type: none"> <li>• Adults and children ≥2 years of age [75]</li> </ul>	<p><i>Highest level of recommendation: 4</i></p> <ul style="list-style-type: none"> <li>• Adults and children ≥6 months to ≤45 years of age [77]</li> </ul>	<p><i>Highest level of recommendation: 4</i></p> <ul style="list-style-type: none"> <li>• Children of all age groups from 6 months to 12 years of age [86]</li> </ul>
Safety	<p><i>Post-marketing surveillance [90]</i></p> <p>Most common AEs reported in the USA, July 1990–June 2002<sup>g</sup></p> <ul style="list-style-type: none"> <li>• Diarrhoea (n = 51), nausea (n = 47), fever (n = 42), abdominal pain (n = 42), headache (n = 31), rash (n = 26), vomiting (n = 21), pain (n = 20), asthenia (n = 17), myalgia (n = 17)</li> </ul>	<p><i>Monograph<sup>h</sup> [75]</i></p> <p>TYPHIM Vi vaccination arm: children aged 12–144 months (n = 175) and adults aged 18–40 years old (n = 152)</p> <ul style="list-style-type: none"> <li>• No serious or unusual side effects in either children or adults</li> </ul> <p><i>Post-marketing surveillance [90]</i></p> <p>Most common AEs reported in the USA, July 1990–June 2002<sup>g</sup></p> <ul style="list-style-type: none"> <li>• Fever (n = 11), headache (n = 11), dizziness (n = 9), rash (n = 9), urticaria (n = 9), myalgia (n = 6), pain (n = 6), abdominal pain (n = 6), pruritis (n = 6), injection site pain (n = 5)</li> </ul>	<p><i>Human challenge study [85]</i></p> <p>Typbar-TCV vaccination arm: adults, n = 41</p> <ul style="list-style-type: none"> <li>• No serious adverse events related to vaccine administration</li> </ul> <p><i>Randomised, double-blind Phase 3 study [92]</i></p> <p>Typbar-TCV vaccination arm: children and adults, n = 667</p> <ul style="list-style-type: none"> <li>• No serious adverse events related to vaccine administration</li> </ul> <p><i>Adverse event reporting during mass vaccination campaign [105]</i></p> <p>Typbar-TCV vaccination arm: children aged 6 months–10 years, n = ~207,000</p> <ul style="list-style-type: none"> <li>• Significantly higher rate of AEs in children aged 6–12 months vs those aged 2–3 years (0.54%)</li> </ul>	<p><i>Randomised comparative trial [91]</i></p> <p>PedaTyph vaccination arm: children aged 3 months–5 years, n = 400</p> <ul style="list-style-type: none"> <li>• Non-severe and recoverable reactions within 48 h</li> <li>• One dose, n = 400, ≥1%: erythema (1.5%), induration (1%), fever (13%), lethargy (1.5%)</li> <li>• Two dose, n = 168, ≥1%: erythema (2%), fever (18%), lethargy (1%)</li> </ul>

(continued on next page)

Table 1 (continued)

Brand and manufacturer	Vivotif® Emergent BioSolutions	TYPHIM Vi® Sanofi Pasteur	Typbar-TCV™ Bharat Biotech	PedaTyph™ Bio-Med
Availability	<ul style="list-style-type: none"> <li>First licensed within Europe in 1983 and in the USA in 1989 [93]</li> <li>Licensed for sale in 26 countries worldwide [94]</li> <li>Recommended by the WHO since 2008 for the control of typhoid in endemic and epidemic settings [73]</li> </ul>	<ul style="list-style-type: none"> <li>Licensed in the USA in 1994 [73]</li> <li>Licensed in over 100 countries [95]</li> <li>Recommended by the WHO since 2008 for the control of typhoid in endemic and epidemic settings [73]</li> </ul>	<ul style="list-style-type: none"> <li>and 0.33%, respectively; <math>p &lt; 0.001</math>)</li> <li>Most common AEs detected via 14-day active follow-up were fever (2.89%) and local reactivity (1.88%)</li> <li>No serious AE was observed</li> <li>Licensed in India in 2013 [96] and Nepal [97]</li> <li>Attained WHO prequalification status in 2018 [97]</li> </ul>	<ul style="list-style-type: none"> <li>Licensed in India in 2008 [73]</li> </ul>

<sup>Δ</sup>Injection site pain was statistically significant,  $p = 0.0499$  [85].

Abbreviations: CI, confidence interval; AE, adverse event; S. Typhi, *Salmonella enterica* subspecies enterica serovar Typhi; WHO, World Health Organization.

<sup>a</sup> The four dose regimen was registered in the USA and Canada in 1987 as a result of the study by Ferreccio and colleagues [81].

<sup>b</sup> Note that information from three additional studies has been excluded as the formulation, dose regimen or time interval between doses does not reflect those in current recommendations. Black and colleagues evaluated the efficacy of one or two doses of Ty21a in a randomised placebo-controlled field study in >80,000 children in Santiago, Chile [102]. Simanjuntak and colleagues evaluated three doses at weekly intervals [98]. Wahdan and colleagues evaluated a liquid formulation in <30,000 children in Egypt [99].

<sup>c</sup> Reference [83] states ages 5–16, reference [84] states ages 5–15.

<sup>d</sup> Efficacy for one dose not reported.

<sup>e</sup> Indirect herd protection has been demonstrated for Typherix® (GlaxoSmithKline), a Vi polysaccharide vaccine [103,106]. Typherix has been withdrawn in some countries [107,108].

<sup>f</sup> This can be used from 3 years of age according to technical data, however as the user has to be able to swallow the whole capsules it is recommended from 5 years of age.

<sup>g</sup> Adverse events for the vaccine when given alone (not in combination with any other vaccine).

<sup>h</sup> This monograph includes data from 2 clinical trials [84,100] as well as data held on file by Sanofi Pasteur.

vaccine is presented in Table 1 and briefly described below. A large-scale randomised, controlled field trial in Santiago, Chile was performed in which school children ( $n = 22,170$ ) received three doses of Ty21a, taken orally every other day, or placebo [80,101]. Results indicated that this regimen confers long-lived protection with 3-year efficacy of 67% [80]. With 7 years' follow-up, efficacy was 62% [101]. Vaccine efficacy increased with age at the time of vaccination, from 59% (95% CI 16–80) in children aged 5–9 years, to 67% (95% CI 35–83) in those aged 10–14, and 85% (95% CI 42–96) in those  $\geq 15$  years old [80]. In another study, analysis of efficacy by age showed increased efficacy in children  $\geq 10$  years versus those aged 5–9 years (53.5% [95% CI 7–77] vs 16.9% [95% CI 0–53]) [87]. The justification for the four-dose regimen employed in the USA and Canada originates from a large randomised field study of Chilean school children, which assessed the comparative efficacy of a two-, three- or four-dose regimen of Ty21a [81]. The incidence of typhoid fever in recipients of two or three doses was significantly higher than in those who received four doses (48% vs 40%,  $p < 0.002$ ) [81]. A subsequent analysis of vaccine efficacy, using data from the two-dose group as standard, reported efficacy of 13% (95% CI 0–33; years 1–3) for those who received three doses and 48% (95% CI 29–62; years 1–3) for those who received four doses [88].

The effectiveness of public health vaccination programmes can depend on both the vaccinated and unvaccinated population. Herd protection is the reduction in infection or disease in the non-immunised proportion of the population as a result of vaccination in another proportion of the population [119]. Evidence that Ty21a can provide indirect herd immunity comes from a field trial in Santiago, Chile, that used one or two doses, during which the incidence of typhoid fever in the control group fell during the follow-up period [102]. The incidence rate in the randomised placebo group in the first year of surveillance was 227 cases per 100,000 school children [102]. The incidence in the second year fell to 139 cases per 100,000 school children [102]. The data suggest that large-scale vaccination appears to cause indirect herd immunity in non-vaccinated subjects [88].

Data regarding co-administration with malaria prophylaxis were

determined using the previously developed liquid formulation, rather than the capsule formulation in current usage, and suggested that the vaccine can be administered concurrently with malaria prophylaxis using atovaquone/proguanil [120]. Current manufacturer recommendations state that vaccination should be completed prior to malaria prophylaxis, with an interval of at least 3 days between the last dose of vaccine and the start of malaria prophylaxis [74].

Ty21a can be administered to immunologically stable HIV-positive individuals (CD4% >25% for children aged <5 years or CD4 count  $\geq 200$  cells/mm<sup>3</sup> if aged  $\geq 5$  years) [73,121]. Ty21a is not recommended for individuals with a known depression of cell-mediated immunity [73]. Ty21a may be given concurrently with the yellow fever vaccine, CVD 103-HgR cholera vaccine and oral polio vaccine [74]. No data are available regarding the interaction with other live attenuated vaccines.

Due to the potential inhibition of the growth of the vaccine organisms and potential attenuation of the immune response, vaccination with Ty21a should be postponed during, and for at least 3 days before and after, antibiotic or antibacterial sulphonamide treatment [74]. For longer-acting antibiotics, eg azithromycin, a longer postponement should be considered [74].

At present there are no data on the safety and immunogenicity of any of the typhoid vaccines in pregnant or lactating women [122]. Generally, live vaccines, and therefore Ty21a, should not be given during pregnancy due to theoretical safety concerns [122], however the manufacturer suggests that it could be administered in cases of increased risk of infection [74].

The efficacy trials of the three- or four-dose alternate-day regimen did not specifically include safety monitoring. However, safety of the Ty21a vaccine can be assessed from post-marketing surveillance data. Post-marketing surveillance data collected in the USA through the Vaccine Adverse Event Reporting System (July 1990 to June 2002; four-dose regimen) revealed 345 reports of adverse events (AEs) related to the administration of Ty21a alone or in combination with other vaccines [90]. The rate of AEs or serious AEs was 9.7 or 0.59 per 100,000 doses, respectively and AEs included diarrhoea, nausea, fever and abdominal

pain [90]. Of 38 million immunisations administered between 1990 and 2000, the total number of spontaneously reported adverse drug reactions was 0.001954% (i.e. ~20 in every million immunisations will result in an adverse drug reaction) [123].

During the early pre-licensure field trials in Chile, there was a considerable level of paratyphoid fever due to *S. Paratyphoid B*, allowing estimation of cross-protection. The Ty21a vaccine has also been shown to confer moderate protection against *S. Paratyphi B* (efficacy 49%) [89]. A randomised double-blind field trial of 20,543 subjects in Plaju, Indonesia (one dose per week for 3 weeks) suggests that Ty21a does not offer cross-protection against *S. Paratyphi A* [98].

## 5.2. Vi polysaccharide vaccine

ViPS vaccines are based on the purified capsular polysaccharide, *S. Typhi* Vi antigen [11]. The Vi antigen of *S. Typhi* is well recognised as a factor for virulence and as an antigen that confers immunity against the typhoid fever [124]. The ViPS induces T cell-independent immune responses against *S. Typhi*, thus resulting in a lack of prolonged protection [97].

Evidence of the efficacy of ViPS vaccines comes from studies that utilised vaccines from two different manufacturers, TYPHIM Vi® (Table 1) and Typherix® (GlaxoSmithKline) vaccines. Typherix vaccine is no longer commercialised in some countries and may be unavailable for use [107,108]. Early pre-licensure randomised studies demonstrated that ViPS vaccines offer a moderate level of protection. A Nepalese study of TYPHIM Vi in subjects aged 5–44 years reported a total efficacy (blood culture proved and clinically suspected) of 75% [82]. A double-blind randomised trial of TYPHIM Vi in South African school children aged 5–15 years reported an efficacy of 55% [84]. A meta-analysis of four individually randomised clinical trials (including the two studies mentioned above plus two additional trials in China utilising locally produced ViPS) demonstrated efficacy of 69% (95% CI 63–74) in year 1 (three trials) and 59% (95% CI 45–69) in year 2 (four trials) [11].

Subgroup analysis by age in a cluster-randomised trial conducted in India using Typherix post-licensure showed the efficacy as: 80% (95% CI 53–91) in children under 5 years; 56% (95% CI 18–77) in those aged 5–14 years; and 46% (95% CI -43–79) in those aged ≥15 and above [103]. To the contrary, a cluster-randomised trial conducted in Pakistan showed no protection among children aged 2–4 years (efficacy -38% [95% CI -192–35]) and 57% (95% CI 6–81) for children 5–16 years old [125].

An outbreak of typhoid fever in previously vaccinated French soldiers stationed in Cote d'Ivoire revealed that an interval of >3 years from the time of vaccination may result in reduced immunity [126].

Hypo-responsiveness or immunotolerance to re-vaccination is the inability of an individual to mount an immune response equal or greater than the immune response induced by primary vaccination [127]. This phenomenon has been described for polysaccharide vaccines [127]. Roggelin and colleagues assessed the influence of previous vaccinations with a ViPS (not more than 5 years ago) on post-vaccination antibody concentrations [128]. Thirty-six of the participants had been vaccinated once, nine had been vaccinated at least twice. There was no evidence of immunotolerance with multiple versus primary vaccination using a ViPS vaccine. However this was a small study, and the subgroup of those who had been previously vaccinated once showed the highest post-vaccination geometric mean antibody concentration compared with those who had been vaccinated twice before or received their primary vaccination [128].

A post-licensure cluster randomised trial in Kolkata, India, indicated that Typherix offers herd immunity. Among unvaccinated members of the vaccine clusters (geographical units that served as units of randomisation), the level of protection was 44% (95% CI 2–69, model based on 25,083 subjects) [103].

ViPS vaccines, because of their poor immunogenic and T cell-

independent properties, are not suitable for immunisation of infants [112]. ViPS vaccines are safe and recommended for HIV-infected individuals [73,121], however elicitation of protective antibodies is directly correlated with the levels of CD4<sup>+</sup> T cells and thus the proportion of individuals with protective antibody concentrations will be lower than in healthy controls [129]. Antibody responses are severely impaired in those with CD4 <200 cells/μL [129].

ViPS vaccines can be co-administered with other vaccines, including inactivated or attenuated, which is relevant for international travellers and routine childhood vaccination schedules [73]. As previously mentioned, there are no data on the safety of typhoid vaccines in pregnant women [122] and thus the manufacturer of TYPHIM Vi recommends that it should only be administered if clearly required and following risk assessment [75].

Post-marketing surveillance data collected in the USA through the Vaccine Adverse Event Reporting System (July 1990 to June 2002) revealed 321 reports of adverse events related to the administration of TYPHIM Vi alone or in combination with other vaccines [90]. The rate of AEs or serious AEs was 4.5 or 0.34 per 100,000 doses, respectively [90]. Common AEs included fever, headache and dizziness [90]. Serious side effects were rare [90].

Neither *S. Paratyphi A* or *B* express the Vi capsular antigen therefore there is no biological plausibility for cross-protection [27]. Theoretically, ViPS should offer protection against *S. Paratyphi C*, which does express the Vi capsular polysaccharide, although this is a rare cause of enteric fever and no data from field trials have reported protection [27].

## 5.3. Typhoid conjugate vaccines

TCVs combine the Vi-polysaccharide capsule with a protein carrier [85]. For example, each dose of PedaTyph contains 5 μg of Vi polysaccharide of *S. Typhi* conjugated to 5 μg of tetanus toxoid [91], a recombinant inactive form of tetanus toxin produced by *Clostridium tetani* [97]. Covalently conjugating ViPS to carrier proteins overcomes the limitation of the ViPS vaccine by changing the immune response from T cell-independent to T cell-dependent, enabling immunisation even in young children [97]. Several conjugate subunit vaccines combining ViPS with another protein antigen (typically inactive forms of bacterial exotoxins) are under investigation [97]. At present, hyporesponsiveness is not thought to be a feature of repeated vaccination with conjugate vaccines [127]. Limited data are currently available – large field studies are required and further investigations are being conducted by the Typhoid Vaccine Acceleration Consortium [130].

Since TCVs are less well established for typhoid vaccination, data are comparatively limited. A Phase 2b randomised controlled trial showed that the efficacy of Typbar-TCV was 54.6% in a controlled human infection model of typhoid fever in adult volunteers aged from 18 to 60 years; a post hoc analysis of these data revealed that if alternative diagnostic criteria were applied, such as fever of 38.0 °C or higher followed by bacteraemia, the estimated efficacy would be 87.1% [85]. In a report of two trials (randomised controlled and an open-label trial), adverse events for Typbar-TCV were uncommon [92]. Fever was the most common, with 4.3% (14/340) of subjects experiencing this AE [92]. Post-marketing surveillance data reported fever, pain and swelling in 1–10% of vaccinees in any age group (no serious AEs were reported) [131]. Whether Typbar-TCV offers herd immunity is unknown at present, however herd immunity has been observed with other conjugate vaccines due to mucosal immunity and will need to be addressed in future studies.

The efficacy of PedaTyph was determined in a single cluster open-label randomised control trial in 950 children aged 6 months to 12 years: year 1 efficacy was reported to be 100% (95% CI 97.6–100) [86]. A study of 400 children to assess the safety and immunogenicity of PedaTyph reported non-severe AEs in 17% of children with one dose, recoverable within 48 h [91]. At present, there is no evidence of interference with other vaccines (e.g. the trivalent measles, mumps and



rubella vaccine) [122]. Although there are no data to this effect, like the ViPS vaccine, it is not biologically plausible for cross-protection to be induced against *S. paratyphoid* A and B. Theoretically, cross-protection against *S. paratyphoid* C is possible.

#### 5.4. Other typhoid conjugate vaccines

There are several other typhoid vaccines available, or in the development pipeline, that utilise a variety of carrier proteins. Vi-rEPA, Vi polysaccharide bound to the recombinant exoprotein of *Pseudomonas aeruginosa*, showed efficacy of >90% in a Phase 3 study of Vietnamese children aged 2–5 years [132] and will be available in China soon [133]. Vi-CRM<sub>197</sub>, Vi polysaccharide conjugated with CRM<sub>197</sub> (a non-toxic mutant of diphtheria toxin), has completed Phase 2 trials in infants, children and adults [134] and is in clinical development [135]. Vi-DT vaccine, Vi polysaccharide conjugated to diphtheria toxoid, is currently undergoing assessment in a Phase 2 trial in children aged 3–23 months [136]. A Phase 3 trial in children and adults is due to complete in January 2020 [137]. In a Phase 1 study in adults aged 18–40 years old and children aged 2–5 years old [138], and in Phase 2 studies in children aged 6 to ≤24 months [139,140], the Vi-DT vaccine has been shown to be well tolerated and immunogenic.

In summary, there are several vaccines available for the prevention of typhoid, the choice of which will include factors such as the local availability and age of the intended recipient.

## 6. Vaccination strategies

A combined approach to typhoid health security based on public health that includes the use of typhoid vaccines, improvements in sanitation and safe water supply is necessary [141]. Vaccination has the potential to decrease the use of antibiotics, limit the emergence of resistant *S. Typhi* strains and create a herd immunity. Consequently, it should be offered to those who reside in endemic regions as well as to travellers to destinations where antibiotic-resistant strains of *S. Typhi* are prevalent [142]. As it is difficult to obtain the output from monitoring and reporting information in real time, and because typhoid fever may not have the highest priority due to competition from other diseases with higher morbidity/mortality, vaccination should be offered irrespective of the intensity of other control strategies [142].

Feedback from regions and countries on the implementation of the Strategic Advisory Group of Experts recommendations on typhoid identified that, as the incidence of *S. Typhi* declines, there has been a concomitant rise in the incidence of *S. Paratyphi* [143]. This increases the uncertainty of the value of typhoid vaccination in the absence of a vaccine against *S. Paratyphi*. In this context, vaccines that offer cross-protection against *S. Paratyphi* (Ty21a for example) may be considered to be of greater value.

### 6.1. Global recommendations for vaccination in endemic areas

The WHO currently recommend vaccination, using Ty21a, ViPS or TCV, to control endemic typhoid fever and outbreaks. The WHO recommends TCV in all ages due to its improved immunological properties, suitability for use in younger children and expected longer duration of protection [73]. Use of ViPS vaccine in individuals aged ≥2 years, and Ty21a vaccine for individuals aged >6 years, is also suitable [73].

#### 6.1.1. Strategies for the introduction of typhoid vaccines

Routine typhoid fever vaccination for public health use has been very limited in the past, even in endemic areas, hampered by the lack of an effective vaccine for young children and relatively short duration of protective efficacy [144–146]. Typbar-TCV attained WHO pre-qualification in 2017 so the current landscape of typhoid vaccine usage is set to change (see Section 6.1.2, “Stakeholders in typhoid vaccine programmes”) [147]. The introduction of TCVs should be

prioritised in countries with the highest burden of typhoid disease or a high burden of antimicrobial resistant *S. Typhi* [73]. Data from Breiman and colleagues showed a high disease burden in densely populated urban slums compared with a low incidence in rural areas, supporting a typhoid immunisation strategy with a geographically and environmentally targeted approach [148].

Studies are ongoing to demonstrate whether the programmed introduction of an effective typhoid vaccine into countries with high burden of disease or significant antimicrobial resistance could have a dramatic impact, protecting children from infection and reducing antimicrobial usage [149]. Health-economics and cost-effectiveness studies suggest that vaccination (using a TCV) is likely highly cost-effective in high-burden settings (>100 cases per 100,000 population) [49]. An age-structured transmission and cost-effectiveness model that simulated multiple vaccination strategies with a TCV showed that TCVs would be highly cost-effective in low-income countries in settings of moderate typhoid incidence (50 cases/100,000 annually) [150].

In countries with epidemiological evidence of high incidence in well-defined subpopulations, a vaccination strategy based on risk assessment should be considered [142]. An evaluation of the cost-effectiveness of ViPS vaccination against typhoid in multiple Asian sites demonstrated that a vaccination programme targeting children would be “very cost-effective” (e.g. costs per disability-adjusted life-years averted less than per-capita gross national income), but programmes that also target adults are less cost-effective (albeit due to the lower incidence in adults than children) [151]. Recent cost-effectiveness analysis in five endemic, low- and middle-income settings showed that routine vaccination with TCVs, as well as one-time catch-up campaigns, would be cost-effective in most settings [152].

A recent study has modelled the predicted impact of TCVs on antimicrobial resistance, using the relative fitness of the resistant strain(s), prevalence of chronic carriers, and rates of recovery without treatment as variables. Notably, herd immunity was not included in the model. The study found that increasing vaccination coverage would decrease the total number of antimicrobial-resistant typhoid infections but not affect the proportion of cases that were antimicrobial resistant [153]. Further evaluation in real-world typhoid-endemic settings is necessary to confirm the model’s predictive results. However, in low-resource settings (where typhoid is endemic), there is little chance of being able to confirm these results. As such, the likely impact of TCVs on antimicrobial resistance remains to be determined.

As asymptomatic carriers are thought to be responsible for maintenance of *S. Typhi* in the human population, a strategy for reducing this reservoir could be of interest. Stratification of carriers by age could support the vaccination strategy in endemic countries.

Interestingly, concomitant administration of Ty21a and ViPS has also been explored [154]. The enhanced immune response observed suggests that usage in this manner should elicit higher protective efficacy, although this is still to be investigated. The authors suggest that concomitant use should be encouraged for those at significant risk [154].

Recent findings from Bhutta and colleagues, studying surveillance data from several countries, documented substantial reductions in typhoid fever burden over recent decades which may be associated with improvements in economic conditions, education and environmental health [155]. It is likely that public health programmes of vaccination could also impact the burden of disease, as has been seen with other pathogens. However, it is possible that differing patterns of urbanisation, and resultant population densities, could impact on the success of vaccination strategies.

Like typhoid, cholera is a bacterium transmitted by faecally contaminated water and it has a high burden of disease, predominantly in areas that lack access to safe water [156]. In 2011, the first low-cost oral cholera vaccine obtained WHO pre-qualification status and efforts began to stockpile the vaccine for use in endemic and epidemic settings [157]. There were operational challenges that hampered the subsequent

vaccination campaigns, including regulatory hurdles, cold chain logistics, and vaccine coverage and uptake, however from 2011 to 2015, 4.8 million doses of cholera vaccine were administered globally [157]. Whilst it may be too early to assess the impact of these vaccinations, surveillance data from Malawi has shown that cholera outbreaks were absent in vaccinated high-risk areas (despite a national outbreak during the surveillance period), suggesting the suitability of this approach [158]. Vaccines have been used with great effect for other endemic diseases, such as polio. Since 1988, when the sustained use of polio vaccines began, the number of countries with endemic polio has reduced from 125 to just two in 2015 (Afghanistan and Pakistan) [93]. Concerted and sustained efforts concerning typhoid vaccinations might similarly result in substantial reductions in the decades to come.

6.1.2. Stakeholders in typhoid vaccine programmes

Several global activities support the introduction of vaccines, with efforts ongoing to make new typhoid vaccines available and accessible to those that need them.

As part of their vaccine investment strategy, Gavi, the Vaccine Alliance, prioritised typhoid vaccines in 2008 but did not make a financial commitment at that time [147]. All vaccines supported by Gavi are supplied through the United Nations procurement process and so pre-qualification is necessary for purchase and subsequent introduction into Gavi-eligible countries [159]. Following the WHO pre-qualification of the TCV vaccine Typhar-TCV in 2017 [147], Gavi approved US\$85 million in funding to support eligible countries to introduce TCVs [160]. At present, there are 58 countries eligible for Gavi funding – to be

eligible, a country's gross national income per capita must be ≤US \$1580 over the previous 3 years [161]. A country's Gavi-eligibility status may have a large influence on a country's vaccine introduction decision and the introduction of TCVs may be more difficult in Gavi-ineligible countries [162].

The Coalition against Typhoid was created with the aim of preventing typhoid among vulnerable populations through research, education and advocacy [163]. The Typhoid Vaccine Acceleration Consortium aim to facilitate the introduction of TCVs into Gavi-eligible countries to reduce the burden of typhoid using an integrated, proactive approach [164]. Through the efforts of these groups and others, progress towards the reduction in typhoid fever is being made.

6.2. Recommendations for travellers to high-risk areas

For individuals in non-endemic areas, typhoid fever impacts travelling populations such as tourists, military personnel, or travellers VFR in endemic areas. Travel destination is the main factor for assessing the risk of acquiring typhoid fever [36]. Other factors include area of stay, duration of stay, purpose of travel and type of accommodation [36]. There are also risk factors intrinsic to the traveller, including age and diagnosed/undiagnosed underlying medical conditions [36]. In those travellers with impaired immunity (e.g. HIV), vaccination is less effective [129].

Vaccination has the potential to decrease the use of antibiotics (both standby and therapeutic use) and limit the emergence of resistant *S. Typhi* strains, and should be offered to travellers to destinations where

**Table 2**  
General vaccine recommendations to prevent typhoid fever for travellers to selected middle and high incidence typhoid fever countries [94,171–188] (incidence as per [14]).

Country recommendations												
	Australia* [171]	Canada [172]	France [173]	Germany [175,188]	Ireland [178,179]	Portugal* [176,177]	Spain** [180,181]		Switzerland [182,183]	The Netherlands [184]	UK [185,186]	USA [187]
	Department of Foreign Affairs and Trade	Department of Foreign Affairs, Trade and Development	Institut Pasteur	German Society of Tropical Medicine	Tropical Medicine Bureau	Sociedade Portuguesa de Medicina do Viajante	Asociación Española de Vacunología	Fundacion IO	Federal Office of Public Health	GGD	National Travel Health Network and Centre	Centers for Disease Control and Prevention
Vaccines												
	Vivotif, TYPHIM Vi, VIVAXIM	Vivotif, TYPHIM Vi, VIVAXIM	Vivotif <sup>§</sup> , TYPHIM Vi	Vivotif <sup>§</sup> , TYPHIM Vi	TYPHIM Vi, VIVAXIM	Vivotif <sup>¶</sup> , TYPHIM Vi, VIVAXIM <sup>¶</sup>	Vivotif, TYPHIM Vi		Vivotif, TYPHIM Vi	Vivotif	Vivotif, TYPHIM Vi, VIVAXIM <sup>¶</sup>	Vivotif,
Destinations in Africa and associated risk factors												
Kenya	All travellers	Some travellers	Some travellers	Some travellers	All travellers	Most travellers	All travellers		Some travellers	None	Most travellers	Most travellers
		A, B, C, D	C, E	E, F, J, L		D, G, H	C, I, J	F, K	G, L		B, C, E, L, M	B, I, N
South Africa	All travellers	Some travellers	Some travellers	Some travellers	All travellers	Most travellers	All travellers	All travellers	Some travellers	None	Most travellers	Most travellers
		A, B, C, D	C, E	E, F, J, L		D, G, H	C, I, J	F, K	B		B, C, E, L, M	B, I, N
Destinations in Asia and associated risk factors												
China	All travellers	Some travellers	Some travellers	Most travellers	All travellers	Most travellers	All travellers	All travellers	Some travellers	Some travellers	Most travellers	Most travellers
		A, B, C, D	C, E	C, E, F, J, L		D, G, H	C, I, J	F, K	G, L	D, O, P	B, C, E, L, M	B, I, N
Malaysia	All travellers	Some travellers	Some travellers	Most travellers	All travellers	Most travellers	All travellers	All travellers	Some travellers	None	Some travellers	Most travellers
		A, B, C, D	C, E	C, E, F, J, L		D, G, H		F, K	G, L		B, C, E, L, M	B, I, N
Destinations in the Indian subcontinent and associated risk factors												
India	All travellers	Most travellers	Some travellers	All travellers	All travellers	Most travellers	All travellers		Some travellers	All travellers	Most travellers	Most travellers
			C, E			D, G, H		F, K	Q	D, O, P	B, C, E, L, M	B, I, N
Pakistan	All travellers	Most travellers	Some travellers	All travellers	All travellers	Most travellers	All travellers		All travellers	All travellers	Most travellers	Most travellers
			C, E			D, G, H		F, K		D, O, P	B, C, E, L, M	B, I, N

\*Recommendations are for typhoid-endemic regions, not country-specific

\*\*Recommendations are for tropical areas, not country-specific

§Vivotif was granted marketing authorization in May 2019 [94] but has not yet been launched

¶Local market name for Vivotif is Typhoral L®

¶Local market name for VIVAXIM is VIATIM®

■Note the licenses for Typherix and Hepatyrrix were cancelled July 2019 [175]

⊗Vivotif was granted marketing authorization in May 2019 [94] and has recently been launched

Risk factor codes: A. Children; B. VFR; C. Extended/longer duration of stay; D. Existing illness/medical condition; E. Poor hygiene conditions/sanitation; F. Increased exposure (e.g. cooperative trips, backpacking, trekking); G. Duration of stay (>4 weeks); H. Activities; I. Visiting small cities/rural areas; J. Contact with the local population; K. Duration of stay (>3 weeks); L. Poor food hygiene; M. Frequency of stays; N. Adventurous eating; O. Duration of stay; P. Circumstance of stay; Q. Duration of stay (>1 week).

antibiotic-resistant strains of *S. Typhi* are prevalent [142]. This is particularly important given that standby antibiotics encourage less cautious use of antibiotics [165]. One of the available licensed products should be offered, namely Ty21a, ViPS or TCV. Licensed combination unconjugated ViPS-hepatitis A vaccines, where available, may also be used for travellers [73].

There is relatively little evidence of the effect of vaccinations in preventing typhoid in travellers who have visited typhoid-endemic areas. Data from 4 years of US national surveillance reported by Mahon and colleagues showed moderate protection (80%) from typhoid fever in vaccinated US travellers who travelled to southern Asia [166]. As the vaccination information gathered from reports did not specify the vaccine administered, the effectiveness of each individual vaccine could not be estimated. In the UK, between 2007 and 2012, >99% of typhoid vaccines prescribed were ViPS vaccines (TYPHIM Vi, Typherix, Hep- atyrix® or VIVAXIM®) [167]. In travellers from England (children ≥2 years and adults) the overall effectiveness of typhoid ViPS vaccines was 65% (95% CI 53–73) [167].

In Canada, the Committee to Advise on Tropical Medicine and Travel suggest that typhoid vaccine (Ty21a or ViPS) be used for Canadian travellers visiting South Asia [168]. In the UK, the National Travel Health Network and Centre generally recommend vaccination for most travellers to typhoid-endemic countries where there is a “medium” disease incidence and the access to improved sanitation is <80% [169]. In the USA, guidelines were updated in 2015, and continue to recommend vaccination for travellers to certain countries, close contacts of chronic carriers, and certain laboratory workers [170].

At present, recommendations worldwide are not harmonised and can be generic or tailored for risk groups (Table 2). Experts must assess vaccination of travellers based on current country-specific recommendations and travel characteristics. Regardless of the incidence rate of typhoid in individual countries, European countries have different vaccination recommendations for travellers to those countries, with the need for vaccination based on travel duration, travel destination, circumstances of travelling or a combination of these factors.

Interviews with staff members from migrant resource centres have revealed that, paradoxically, migrants may believe that they are at lower risk than non-VFR travellers [34]. This is in part due to a generalised perception of immunity that they hold [34]. Efforts should be increased to target this sub-group of travellers.

As typhoid vaccines do not offer complete protection, safe water, sanitation and hygiene interventions are critical to preventing the spread of typhoid, both in endemic settings and among travellers [189]. A multidisciplinary strategy of public health based on personal protection and infrastructure interventions is needed.

## 7. Conclusion

Resistance has become a major threat to the treatment of typhoid, leading to treatment failure and subsequent changes in antimicrobial policy. The increasing prevalence of MDR *S. Typhi* strains is an important factor in the development of vaccination strategies for the prevention of typhoid infection in high-risk populations. The use of TCVs in endemic regions may be the best defence against MDR *S. Typhi* [54]. There is a need for worldwide surveillance and access to information on resistant strains, parallel to improvements in antibiotic usage and stewardship.

Country-level decision-making and programme planning are critical for local uptake and sustainability of vaccination strategies [122]. National decisions on the preferred vaccination strategy should be based on an analysis of the disease burden and risk factors for transmission, availability and quality of surveillance data, affordability, and operational feasibility. In parallel to vaccination, efforts to improve sanitation should continue.

For travellers, harmonisation of recommendations is likely to be of benefit. In particular, greater effort should be made to encourage

vaccination for those visiting family and friends.

## Author contributions

Cristina Masuet-Aumatell: Conceptualization, Writing - Original draft preparation, Writing - Reviewing and Editing.

Jorge Atouguia: Conceptualization, Writing - Original draft preparation, Writing - Reviewing and Editing.

## Funding source

The manuscript was funded by Emergent BioSolutions. The study sponsors had no role in the writing of the manuscript or the decision to submit the manuscript for publication.

## Declaration of competing interest

The authors declare no conflicts of interest.

## Acknowledgements

Medical writing support was provided by Corrinne Segal, PhD, of Elements Communications Ltd, and funded by Emergent BioSolutions.

## References

- Parry CM, Hien TT, Dougan G, White NJ, Farrar JJ. Typhoid fever. *N Engl J Med* 2002;347(22):1770–82. <https://doi.org/10.1056/NEJMra020201>.
- Crump JA, Sjolund-Karlsson M, Gordon MA, Parry CM. Epidemiology, clinical presentation, laboratory diagnosis, antimicrobial resistance, and antimicrobial management of invasive Salmonella infections. *Clin Microbiol Rev* 2015;28(4): 901–37. <https://doi.org/10.1128/cmr.00002-15>.
- Connor BA, Schwartz E. Typhoid and paratyphoid fever in travellers. *Lancet Infect Dis* 2005;5(10):623–8. [https://doi.org/10.1016/s1473-3099\(05\)70239-5](https://doi.org/10.1016/s1473-3099(05)70239-5).
- Meltzer E, Sadik C, Schwartz E. Enteric fever in Israeli travelers: a nationwide study. *J Trav Med* 2005;12(5):275–81. <https://doi.org/10.2310/7060.2005.12507>.
- Freedman DO, Weld LH, Kozarsky PE, Fisk T, Robins R, von Sonnenburg F, et al. Spectrum of disease and relation to place of exposure among ill returned travelers. *N Engl J Med* 2006;354(2):119–30. <https://doi.org/10.1056/NEJMoa051331>.
- Ekdahl K, de Jong B, Andersson Y. Risk of travel-associated typhoid and paratyphoid fevers in various regions. *J Trav Med* 2005;12(4):197–204. <https://doi.org/10.2310/7060.2005.12405>.
- Andrews JR, Qamar FN, Charles RC, Ryan ET. Extensively drug-resistant typhoid - are conjugate vaccines arriving just in time? *N Engl J Med* 2018;379(16): 1493–5. <https://doi.org/10.1056/NEJMp1803926>.
- Wong VK, Baker S, Pickard DJ, Parkhill J, Page AJ, Feasey NA, et al. Phylogeographical analysis of the dominant multidrug-resistant H58 clade of Salmonella Typhi identifies inter- and intracontinental transmission events. *Nat Genet* 2015;47(6):632–9. <https://doi.org/10.1038/ng.3281>.
- Buckle GC, Walker CL, Black RE. Typhoid fever and paratyphoid fever: systematic review to estimate global morbidity and mortality for 2010. *J Glob Health* 2012;2(1):010401. <https://doi.org/10.7189/jogh.02.010401>.
- Wain J, Hendriksen RS, Mikoleit ML, Keddy KH, Ochiai RL. Typhoid fever. *Lancet* 2015;385(9973):1136–45. [https://doi.org/10.1016/s0140-6736\(13\)62708-7](https://doi.org/10.1016/s0140-6736(13)62708-7).
- Milligan R, Paul M, Richardson M, Neuberger A. Vaccines for preventing typhoid fever. *Cochrane Database Syst Rev* 2018;5:Cd001261. <https://doi.org/10.1002/14651858.CD001261.pub4>.
- Steele AD, Hay Burgess DC, Diaz Z, Carey ME, Zaidi AK. Challenges and opportunities for typhoid fever control: a call for coordinated action. *Clin Infect Dis* 2016;62(Suppl 1):S4–8. <https://doi.org/10.1093/cid/civ976>.
- Antillon M, Warren JL, Crawford FW, Weinberger DM, Kurum E, Pak GD, et al. The burden of typhoid fever in low- and middle-income countries: a meta-regression approach. *PLoS Negl Trop Dis* 2017;11(2):e0005376. <https://doi.org/10.1371/journal.pntd.0005376>.
- Mogasale V, Maskery B, Ochiai RL, Lee JS, Mogasale VV, Ramani E, et al. Burden of typhoid fever in low-income and middle-income countries: a systematic, literature-based update with risk-factor adjustment. *Lancet Glob Health* 2014;2(10):e570–80. [https://doi.org/10.1016/s2214-109x\(14\)70301-8](https://doi.org/10.1016/s2214-109x(14)70301-8).
- Baker S, Hombach J, Marks F. What have we learned from the typhoid fever surveillance in Africa Program? *Clin Infect Dis* 2016;62(Suppl 1):S1–3. <https://doi.org/10.1093/cid/civ675>.
- GBD 2017 Typhoid, Paratyphoid Collaborators. The global burden of typhoid and paratyphoid fevers: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet Infect Dis* 2019;19(4):369–81. [https://doi.org/10.1016/s1473-3099\(18\)30685-6](https://doi.org/10.1016/s1473-3099(18)30685-6).



- [17] Marks F, von Kalckreuth V, Aaby P, Adu-Sarkodie Y, El Tayeb MA, Ali M, et al. Incidence of invasive salmonella disease in sub-Saharan Africa: a multicentre population-based surveillance study. *Lancet Glob Health* 2017;5(3):e310–23. [https://doi.org/10.1016/s2214-109x\(17\)30022-0](https://doi.org/10.1016/s2214-109x(17)30022-0).
- [18] Bhan MK, Bahl R, Bhatnagar S. Typhoid and paratyphoid fever. *Lancet* 2005;366(9487):749–62. [https://doi.org/10.1016/s0140-6736\(05\)67181-4](https://doi.org/10.1016/s0140-6736(05)67181-4).
- [19] Gunn JS, Marshall JM, Baker S, Dongol S, Charles RC, Ryan ET. Salmonella chronic carriage: epidemiology, diagnosis, and gallbladder persistence. *Trends Microbiol* 2014;22(11):648–55. <https://doi.org/10.1016/j.tim.2014.06.007>.
- [20] Levine MM, Black RE, Lanata C. Precise estimation of the numbers of chronic carriers of Salmonella typhi in Santiago, Chile, an endemic area. *J Infect Dis* 1982;146(6):724–6. <https://doi.org/10.1093/infdis/146.6.724>.
- [21] Schioler H, Christiansen ED, Hoybye G, Rasmussen SN, Greibe J. Biliary calculi in chronic Salmonella carriers and healthy controls: a controlled study. *Scand J Infect Dis* 1983;15(1):17–9. <https://doi.org/10.3109/inf.1983.15.issue-1.04>.
- [22] Neiger MR, Gonzalez JF, Gonzalez-Escobedo G, Kuck H, White P, Gunn JS. Pathoadaptive alteration of Salmonella biofilm formation in response to the gallbladder environment. *J Bacteriol* 2019;201(14). <https://doi.org/10.1128/jb.00774-18>.
- [23] White AP, Gibson DL, Kim W, Kay WW, Surette MG. Thin aggregative fimbriae and cellulose enhance long-term survival and persistence of Salmonella. *J Bacteriol* 2006;188(9):3219–27. <https://doi.org/10.1128/jb.188.9.3219-3227.2006>.
- [24] N'Cho HS, Masunda KPE, Mukeredzi I, Manangazira P, Govore E, Duri C, et al. Notes from the field: typhoid fever outbreak - Harare, Zimbabwe. *MMWR Morb Mortal Wkly Rep* 2019;68(2):44–5. <https://doi.org/10.15585/mmwr.mm6802a5>. October 2017-February 2018.
- [25] Siddiqui TR, Bibi S, Mustafa MA, Ayaz SM, Khan A. High prevalence of typhoidal Salmonella enterica serovars excreting food handlers in Karachi-Pakistan: a probable factor for regional typhoid endemicity. *J Health Popul Nutr* 2015;33:27. <https://doi.org/10.1186/s41043-015-0037-6>.
- [26] Mogaale VV, Ramani E, Mogaale V, Park JY, Wierzb TF. Estimating typhoid fever risk associated with lack of access to safe water: a systematic literature review. *J Environ Public Health* 2018;2018:9589208. <https://doi.org/10.1155/2018/9589208>.
- [27] World Health Organization. The immunological basis for immunization series: module 20: Salmonella enterica serovar Typhi (typhoid vaccines). <https://apps.who.int/iris/handle/10665/44752>. [Accessed 11 October 2019].
- [28] Kacprzak E, Stefaniak J, Skoryna-Karcz B, Wojtacha A, Bolewska B, Juszczyk J. Diagnostic difficulties in febrile travellers returning from the tropics. Two cases of typhoid fever imported from India. *Pol Merkurius Lek* 2002;13(78):509–15.
- [29] Public Health England. Enteric fever (typhoid and paratyphoid): England, Wales and Northern Ireland. [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment\\_data/file/761348/Enteric\\_fever\\_annual\\_report\\_2017.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/761348/Enteric_fever_annual_report_2017.pdf). [Accessed 17 October 2019].
- [30] Comeau JL, Tran TH, Moore DL, Phi CM, Quach C. Salmonella enterica serotype Typhi infections in a Canadian pediatric hospital: a retrospective case series. *CMAJ Open* 2013;1(1):E56–61. <https://doi.org/10.9778/cmajo.20120012>.
- [31] Centers for Disease Control and Prevention. National typhoid and paratyphoid fever surveillance annual summary. <https://www.cdc.gov/typhoid-fever/reports/annual-report-2015.html>. [Accessed 17 October 2019].
- [32] Koch Institute Robert. Infektionsepidemiologisches Jahrbuch meldepflichtiger Krankheiten für. [https://www.rki.de/DE/Content/Infekt/Jahrbuch/Jahrbuch\\_2018.pdf?\\_blob=publicationFile](https://www.rki.de/DE/Content/Infekt/Jahrbuch/Jahrbuch_2018.pdf?_blob=publicationFile). [Accessed 17 October 2019].
- [33] European Centre for Disease Prevention and Control. Surveillance report. Annual epidemiological report for 2016: typhoid and paratyphoid fevers. [https://ecdc.europa.eu/sites/portal/files/documents/AER\\_for\\_2016-typhoid-paratyphoid-fevers.pdf](https://ecdc.europa.eu/sites/portal/files/documents/AER_for_2016-typhoid-paratyphoid-fevers.pdf). [Accessed 17 October 2019].
- [34] Seale H, Kaur R, Mahimbo A, MacIntyre CR, Zwar N, Smith M, et al. Improving the uptake of pre-travel health advice amongst migrant Australians: exploring the attitudes of primary care providers and migrant community groups. *BMC Infect Dis* 2016;16:213. <https://doi.org/10.1186/s12879-016-1479-1>.
- [35] Sorrell T, Selig DJ, Riddle MS, Porter CK. Typhoid fever cases in the U.S. military. *BMC Infect Dis* 2015;15:424. <https://doi.org/10.1186/s12879-015-1159-6>.
- [36] Smeti P, Pavli A, Katerelos P, Maltezos HC. Typhoid vaccination for international travelers from Greece visiting developing countries. *J Trav Med* 2014;21(2):99–103. <https://doi.org/10.1111/jtm.12076>.
- [37] Steinberg EB, Bishop R, Haber P, Dempsey AF, Hoekstra RM, Nelson JM, et al. Typhoid fever in travelers: who should be targeted for prevention? *Clin Infect Dis* 2004;39(2):186–91. <https://doi.org/10.1086/421945>.
- [38] Wijedoru L, Mallett S, Parry CM. Rapid diagnostic tests for typhoid and paratyphoid (enteric) fever. *Cochrane Database Syst Rev* 2017;5:CD008892. <https://doi.org/10.1002/14651858.CD008892.pub2>.
- [39] Ajibola O, Mshelia MB, Gulumbe BH, Eze AA. Typhoid fever diagnosis in endemic countries: a clog in the wheel of progress? *Medicina* 2018;54(2):23. <https://doi.org/10.3390/medicina54020023>.
- [40] Andualet G, Abebe T, Kebede N, Gebre-Selassie S, Mihret A, Alemayehu H. A comparative study of Widal test with blood culture in the diagnosis of typhoid fever in febrile patients. *BMC Res Notes* 2014;7:653. <https://doi.org/10.1186/1756-0500-7-653>.
- [41] Olsen SJ, Pruckler J, Bibb W, Nguyen TM, Tran MT, Nguyen TM, et al. Evaluation of rapid diagnostic tests for typhoid fever. *J Clin Microbiol* 2004;42(5):1885–9. <https://doi.org/10.1128/jcm.42.5.1885-1889.2004>.
- [42] Patki R, Lilani S, Lanjewar D. Baseline antibody titre against Salmonella enterica in healthy population of Mumbai, Maharashtra, India. *Internet J Microbiol* 2017;2017:9042125. <https://doi.org/10.1155/2017/9042125>.
- [43] Klemm EJ, Shakoor S, Page AJ, Qamar FN, Judge K, Saeed DK, et al. Emergence of an extensively drug-resistant Salmonella enterica serovar typhi clone harboring a promiscuous plasmid encoding resistance to fluoroquinolones and third-generation cephalosporins. *mBio* 2018;9(1). <https://doi.org/10.1128/mBio.00105-18>.
- [44] Keddy KH, Sooka A, Letsoalo ME, Hoyland G, Chaignat CL, Morrissey AB, et al. Sensitivity and specificity of typhoid fever rapid antibody tests for laboratory diagnosis at two sub-Saharan African sites. *Bull World Health Organ* 2011;89(9):640–7. <https://doi.org/10.2471/blt.11.087627>.
- [45] Islam K, Sayeed MA, Hossen E, Khanam F, Charles RC, Andrews J, et al. Comparison of the performance of the TPTest, Tubex, Typhidot and Widal immunodiagnostic assays and blood cultures in detecting patients with typhoid fever in Bangladesh, including using a Bayesian latent class modeling approach. *PLoS Negl Trop Dis* 2016;10(4):e0004558. <https://doi.org/10.1371/journal.pntd.0004558>.
- [46] Ismail A. New advances in the diagnosis of typhoid and detection of typhoid carriers. *Malays J Med Sci* 2000;7(2):3–8.
- [47] Kariuki S, Gordon MA, Feasey N, Parry CM. Antimicrobial resistance and management of invasive Salmonella disease. *Vaccine* 2015;33(Suppl 3):C21–9. <https://doi.org/10.1016/j.vaccine.2015.03.102>.
- [48] Samajpati S, Das S, Ray U, Dutta S. Report of relapse typhoid fever cases from Kolkata, India: recrudescence or reinfection? *Jpn J Infect Dis* 2018;71(3):209–13. <https://doi.org/10.7883/yoken.JJID.2017.321>.
- [49] Andrews JR, Baker S, Marks F, Alsan M, Garrett D, Gellin BG, et al. Typhoid conjugate vaccines: a new tool in the fight against antimicrobial resistance. *Lancet Infect Dis* 2019;19(1):e26–30. [https://doi.org/10.1016/s1473-3099\(18\)30350-5](https://doi.org/10.1016/s1473-3099(18)30350-5).
- [50] Tatavarthy A, Luna VA, Amuso PT. How multidrug resistance in typhoid fever affects treatment options. *Ann N Y Acad Sci* 2014;1323:76–90. <https://doi.org/10.1111/nyas.12490>.
- [51] Holt KE, Phan MD, Baker S, Duy PT, Nga TV, Nair S, et al. Emergence of a globally dominant InChII plasmid type associated with multiple drug resistant typhoid. *PLoS Negl Trop Dis* 2011;5(7):e1245. <https://doi.org/10.1371/journal.pntd.0001245>.
- [52] Yap KP, Thong KL. Salmonella typhi genomics: envisaging the future of typhoid eradication. *Trop Med Int Health* 2017;22(8):918–25. <https://doi.org/10.1111/tmi.12899>.
- [53] Phan MD, Kidgell C, Nair S, Holt KE, Turner AK, Hinds J, et al. Variation in Salmonella enterica serovar typhi InChII plasmids during the global spread of resistant typhoid fever. *Antimicrob Agents Chemother* 2009;53(2):716–27. <https://doi.org/10.1128/aac.00645-08>.
- [54] Britto CD, Wong VK, Dougan G, Pollard AJ. A systematic review of antimicrobial resistance in Salmonella enterica serovar Typhi, the etiologic agent of typhoid. *PLoS Negl Trop Dis* 2018;12(10):e0006779. <https://doi.org/10.1371/journal.pntd.0006779>.
- [55] Park SE, Phan DT, Boinett C, Wong VK, Pak GD, Panzner U, et al. The phylogeography and incidence of multi-drug resistant typhoid fever in sub-Saharan Africa. *Nat Commun* 2018;9(1):5094. <https://doi.org/10.1038/s41467-018-07370-z>.
- [56] Dyson ZA, Klemm EJ, Palmer S, Dougan G. Antibiotic resistance and typhoid. *Clin Infect Dis* 2019;68(Suppl 2):S165–70. <https://doi.org/10.1093/cid/ciy1111>.
- [57] Effa EE, Lassi ZS, Critchley JA, Garner P, Sinclair D, Olliaro PL, et al. Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever). *Cochrane Database Syst Rev* 2011;10:CD004530. <https://doi.org/10.1002/14651858.CD004530.pub4>.
- [58] Janjua H. Drug-resistant superbug to blame for deadly typhoid outbreak in Pakistan 2018. *The Guardian Web site*, <https://www.theguardian.com/global-development/2018/feb/22/drug-resistant-superbug-deadly-typhoid-outbreak-pakistan>. [Accessed 18 March 2019].
- [59] Saleem Z, Hassali MA. Travellers take heed: outbreak of extensively drug resistant (XDR) typhoid fever in Pakistan and a warning from the US CDC. *Trav Med Infect Dis* 2019;27:127. <https://doi.org/10.1016/j.tmaid.2018.10.013>.
- [60] Regional Office for the Eastern Mediterranean (WHO). Disease outbreaks in Eastern Mediterranean Region (EMR), January to December 2018. *Weekly Epidemiological Monitor* 2018;11(52).
- [61] ProMED-mail. Typhoid fever - Pakistan (03): (Sindh) multidrug resistance (20190626.6539573). <http://www.promedmail.org/>. [Accessed 26 June 2019].
- [62] Bhutta ZA, Ahmed I, Als D, Radhakrishnan A, Qamar FN, Stanaway JD, et al. Antimicrobial resistance in typhoid: implications for policy and immunization strategies. *SAGE*; 2016. [https://www.who.int/immunization/sage/meetings/2017/october/3\\_Bhutta\\_Typhoid\\_SAGE\\_16Oct2017.pdf](https://www.who.int/immunization/sage/meetings/2017/october/3_Bhutta_Typhoid_SAGE_16Oct2017.pdf). [Accessed 19 March 2019].
- [63] Ahmad KA, Khan LH, Roshan B, Bhutta ZA. Factors associated with typhoid relapse in the era of multiple drug resistant strains. *J Infect Dev Ctries* 2011;5(10):727–31. <https://doi.org/10.3855/jidc.1192>.
- [64] Blumentrath CG, Muller G, Teichmann D, Tiesmeier J, Petridou J. Relapse of typhoid fever following delayed response to meropenem: a case report and review of previously published cases indicating limited clinical efficacy of meropenem for the treatment of typhoid fever. *Ger Med Sci* 2019;17:Doc01. <https://doi.org/10.3205/000267>.
- [65] Ferreccio C, Morris Jr JG, Valdivieso C, Prenzel I, Sotomayor V, Drusano GL, et al. Efficacy of ciprofloxacin in the treatment of chronic typhoid carriers. *J Infect Dis* 1988;157(6):1235–9. <https://doi.org/10.1093/infdis/157.6.1235>.
- [66] Gonzalez-Lopez JJ, Piedra-Carrasco N, Salvador F, Rodriguez V, Sanchez-Montalva A, Planes AM, et al. ESBL-producing Salmonella enterica serovar typhi



- in traveler returning from Guatemala to Spain. *Emerg Infect Dis* 2014;20(11): 1918–20. <https://doi.org/10.3201/eid2011.140525>.
- [67] Pfeifer Y, Matten J, Rabsch W. Salmonella enterica serovar Typhi with CTX-M beta-lactamase, Germany. *Emerg Infect Dis* 2009;15(9):1533–5. <https://doi.org/10.3201/eid1509.090567>.
- [68] Date KA, Newton AE, Medalla F, Blackstock A, Richardson L, McCullough A, et al. Changing patterns in enteric fever incidence and increasing antibiotic resistance of enteric fever isolates in the United States, 2008–2012. *Clin Infect Dis* 2016;63(3):322–9. <https://doi.org/10.1093/cid/ciw232>.
- [69] Chatham Stephens K, Medalla F, Hughes M, Appiah GD, Aubert RD, Caidi H, et al. Emergence of extensively drug-resistant Salmonella Typhi infections among travelers to or from Pakistan - United States, 2016–2018. *MMWR Morb Mortal Wkly Rep* 2019;68(1):11–3. <https://doi.org/10.15585/mmwr.mm6801a3>.
- [70] Engsbro AL, Riis Jespersen HS, Goldschmidt MI, Mollerup S, Worming P, Pedersen MS, et al. Ceftriaxone-resistant Salmonella enterica serotype Typhi in a pregnant traveller returning from Karachi, Pakistan to Denmark, 2019. *Euro Surveill* 2019;24(21). <https://doi.org/10.2807/1560-7917.19000289>.
- [71] Howard-Jones A, Kesson AM, Outhred AC, Britton PN. First reported case of extensively drug-resistant typhoid in Australia. *Med J Aust* 2019;211(6):286–e1. <https://doi.org/10.5694/mja2.50316>.
- [72] World Health Organization. Typhoid fever - Pakistan (07): multidrug resistance. <https://www.who.int/csr/don/27-december-2018-typhoid-pakistan/en/>. [Accessed 17 October 2019].
- [73] World Health Organization. Typhoid vaccines: WHO position paper – March 2018. *Wkly Epidemiol Rec* 2018;93:153–72.
- [74] Emergent BioSolutions. Vivotif: summary of product characteristics. [http://www.paxvax.co.uk/file-manager/New-leaflets/spc-vivotif\\_smpc\\_july2018.pdf](http://www.paxvax.co.uk/file-manager/New-leaflets/spc-vivotif_smpc_july2018.pdf). [Accessed 17 October 2019].
- [75] Pasteur Sanofi. TYPHIM Vi®: Salmonella typhi vi capsular polysaccharide vaccine (monograph). Published 2018, <http://products.sanofi.ca/en/typhim.pdf>. [Accessed 8 October 2019].
- [76] Pasteur Sanofi. VIVAXIM® data sheet. [http://products.sanofi.com.au/vaccines/VIVAXIM\\_NZ\\_PL.pdf](http://products.sanofi.com.au/vaccines/VIVAXIM_NZ_PL.pdf). [Accessed 17 October 2019].
- [77] Biotech Bharat. Typhoid (vi capsular polysaccharide) - tetanus toxoid conjugate vaccine. <https://www.bharatbiotech.com/images/typbartcv/Typhoid-TCV-Package-Insert.pdf>. [Accessed 17 October 2019].
- [78] Bio-Med. Typhoid Vi conjugate vaccine I.P. Peda Typh 2017. <http://www.biom-ed.co.in/wp-content/uploads/2017/12/PEDA-TYPH.pdf>. [Accessed 17 October 2019].
- [79] Emergent BioSolutions. Typhoid vaccine live oral Ty21a: Vivotif. [https://www.paxvaxconnect.com/PDF/Vivotif\\_Prescribing\\_Information.pdf](https://www.paxvaxconnect.com/PDF/Vivotif_Prescribing_Information.pdf). [Accessed 17 October 2019].
- [80] Levine M, Black R, Ferreccio C, Germanier R. Large-scale field trial of Ty21a live oral typhoid vaccine in enteric-coated capsule formulation. *Lancet* 1987;329(8541):1049–52. [https://doi.org/10.1016/S0140-6736\(87\)90480-6](https://doi.org/10.1016/S0140-6736(87)90480-6).
- [81] Ferreccio C, Levine MM, Rodriguez H, Contreras R. Comparative efficacy of two, three, or four doses of TY21a live oral typhoid vaccine in enteric-coated capsules: a field trial in an endemic area. *J Infect Dis* 1989;159(4):766–9. <https://doi.org/10.1093/infdis/159.4.766>.
- [82] Acharya IL, Lowe CU, Thapa R, Gurubacharya VL, Shrestha MB, Cadoz M, et al. Prevention of typhoid fever in Nepal with the Vi capsular polysaccharide of Salmonella typhi. A preliminary report. *N Engl J Med* 1987;317(18):1101–4. <https://doi.org/10.1056/nejm198710293171801>.
- [83] Klugman KP, Gilbertson IT, Koornhof HJ, Robbins JB, Schneerson R, Schulz D, et al. Protective activity of Vi capsular polysaccharide vaccine against typhoid fever. *Lancet* 1987;2(8569):1165–9. [https://doi.org/10.1016/S0140-6736\(87\)91316-X](https://doi.org/10.1016/S0140-6736(87)91316-X).
- [84] Klugman KP, Koornhof HJ, Robbins JB, Le Cam NN. Immunogenicity, efficacy and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunization. *Vaccine* 1996;14(5): 435–8. [https://doi.org/10.1016/0264-410x\(95\)00186-5](https://doi.org/10.1016/0264-410x(95)00186-5).
- [85] Jin C, Gibani MM, Moore M, Juel HB, Jones E, Meiring J, et al. Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trial. *Lancet* 2017;390(10111):2472–80. [https://doi.org/10.1016/S0140-6736\(17\)32149-9](https://doi.org/10.1016/S0140-6736(17)32149-9).
- [86] Mitra M, Shah N, Ghosh A, Chatterjee S, Kaur I, Bhattacharya N, et al. Efficacy and safety of vi-tetanus toxoid conjugated typhoid vaccine (PedaTyph™) in Indian children: school based cluster randomized study. *Hum Vaccines Immunother* 2016;12(4):939–45. <https://doi.org/10.1080/21645515.2015.1117715>.
- [87] Levine MM, Ferreccio C, Cryz S, Ortiz E. Comparison of enteric-coated capsules and liquid formulation of Ty21a typhoid vaccine in randomised controlled field trial. *Lancet* 1990;336(8720):891–4. [https://doi.org/10.1016/0140-6736\(90\)92266-k](https://doi.org/10.1016/0140-6736(90)92266-k).
- [88] Levine MM, Ferreccio C, Black RE, Tacket CO, Germanier R. Progress in vaccines against typhoid fever. *Rev Infect Dis* 1989;11(Suppl 3):S552–567. [https://doi.org/10.1093/clinids/11.supplement\\_3.s552](https://doi.org/10.1093/clinids/11.supplement_3.s552).
- [89] Levine MM, Ferreccio C, Black RE, Lagos R, San Martin O, Blackwelder WC. Ty21a live oral typhoid vaccine and prevention of paratyphoid fever caused by Salmonella enterica serovar paratyphi B. *Clin Infect Dis* 2007;45(Suppl 1): S24–28. <https://doi.org/10.1086/518141>.
- [90] Begier EM, Burwen DR, Haber P, Ball R. Postmarketing safety surveillance for typhoid fever vaccines from the vaccine adverse event reporting system, July 1990 through June 2002. *Clin Infect Dis* 2004;38(6):771–9. <https://doi.org/10.1086/381548>.
- [91] Chinnasami B, Mangayarkarasi V, Prema A, Sadasivam K, Davis MJ. Safety and immunogenicity of Salmonella typhi Vi conjugate vaccine (Peda Typh™) in children upto five years. *Int J Sci Res* 2013;3(2). <https://doi.org/10.7860/JCDR/2015/13302.5903>.
- [92] Mohan VK, Varanasi V, Singh A, Pasetti MF, Levine MM, Venkatesan R, et al. Safety and immunogenicity of a Vi polysaccharide-tetanus toxoid conjugate vaccine (Typhar-TCV) in healthy infants, children, and adults in typhoid endemic areas: a multicenter, 2-cohort, open-label, double-blind, randomized controlled phase 3 study. *Clin Infect Dis* 2015;61(3):393–402. <https://doi.org/10.1093/cid/civ295>.
- [93] World Health Organization. Polio vaccines: WHO position paper - March, 2016. *Wkly Epidemiol Rec* 2016;91(12):145–68.
- [94] Emergent BioSolutions. Emergent BioSolutions announces granting of marketing authorization in five EU Countries for its oral typhoid vaccine; expands availability across Europe. [https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-announces-granting-marketing-authorization?field\\_nir\\_news\\_date\\_value\[min\]=2019](https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-announces-granting-marketing-authorization?field_nir_news_date_value[min]=2019). [Accessed 17 October 2019].
- [95] Grand Lyon. Sanofi Pasteur: typhoid vaccine granted prequalification by the world health organization. <http://www.business.greaterlyon.com/news/sanofi-pasteur-typhoid-vaccine-granted-prequalification-by-the-world-health-organization-532.html>. [Accessed 17 October 2019].
- [96] Sahastrabudde S, Saluja T. Overview of the typhoid conjugate vaccine pipeline: current status and future plans. *Clin Infect Dis* 2019;68(Suppl 1):S22–26. <https://doi.org/10.1093/cid/ciy884>.
- [97] Yang YA, Chong A, Song J. Why is eradicating typhoid fever so challenging: implications for vaccine and therapeutic design. *Vaccines* 2018;6(3). <https://doi.org/10.3390/vaccines6030045>.
- [98] Simanjuntak CH, Paleologo FP, Punjabi NH, Darmowigoto R, Soeprawoto, Totosudirjo H, et al. Oral immunisation against typhoid fever in Indonesia with Ty21a vaccine. *Lancet* 1991;338(8774):1055–9. [https://doi.org/10.1016/0140-6736\(91\)91910-m](https://doi.org/10.1016/0140-6736(91)91910-m).
- [99] Wahdan MH, Serie C, Cerisier Y, Sallam S, Germanier R. A controlled field trial of live Salmonella typhi strain Ty 21a oral vaccine against typhoid: three-year results. *J Infect Dis* 1982;145(3):292–5. <https://doi.org/10.1093/infdis/145.3.292>.
- [100] Keitel WA, Bond NL, Zahradnik JM, Cramton TA, Robbins JB. Clinical and serological responses following primary and booster immunization with Salmonella typhi Vi capsular polysaccharide vaccines. *Vaccine* 1994;12(3):195–9. [https://doi.org/10.1016/0264-410x\(94\)90194-5](https://doi.org/10.1016/0264-410x(94)90194-5).
- [101] Levine MM, Ferreccio C, Abrego P, Martin OS, Ortiz E, Cryz S. Duration of efficacy of Ty21a, attenuated Salmonella typhi live oral vaccine. *Vaccine* 1999;17(Suppl 2):S22–27. [https://doi.org/10.1016/S0264-410x\(99\)00231-5](https://doi.org/10.1016/S0264-410x(99)00231-5).
- [102] Black RE, Levine MM, Ferreccio C, Clements ML, Lanata C, Rooney J, et al. Efficacy of one or two doses of Ty21a Salmonella typhi vaccine in enteric-coated capsules in a controlled field trial. Chilean Typhoid Committee. *Vaccine* 1990;8(1):81–4. [https://doi.org/10.1016/0264-410x\(90\)90183-m](https://doi.org/10.1016/0264-410x(90)90183-m).
- [103] Sur D, Ochiai RL, Bhattacharya SK, Ganguly NK, Ali M, Manna B, et al. A cluster-randomized effectiveness trial of Vi typhoid vaccine in India. *N Engl J Med* 2009; 361(4):335–44. <https://doi.org/10.1056/NEJMoa0807521>.
- [104] Shakya M, Colin-Jones R, Theiss-Nyland K, Voysey M, Pant D, Smith N, et al. Phase 3 efficacy analysis of a typhoid conjugate vaccine trial in Nepal. *N Engl J Med* 2019;381(23):2209–18. <https://doi.org/10.1056/NEJMoa1905047>.
- [105] Qamar FN, Yousafzai MT, Khaliq A, Karim S, Memon H, Junejo A, et al. Adverse events following immunization with typhoid conjugate vaccine in an outbreak setting in Hyderabad. Pakistan. *Vaccine* 2020;38(19):3518–23. <https://doi.org/10.1016/j.vaccine.2020.03.028>.
- [106] Ali M, Sur D, Kanungo S, Qadri F, Kim DR, Islam T, et al. Re-evaluating herd protection by Vi typhoid vaccine in a cluster randomized trial. *Int Health* 2020;12(1):36–42. <https://doi.org/10.1093/inthealth/ihz069>.
- [107] GlaxoSmithKline. Discontinuation of Typherix adult vaccine. Published 2018, <https://au.gsk.com/en-au/media/press-releases/2018/discontinuation-of-typherix-x-adult-vaccine/>. [Accessed 16 October 2019].
- [108] NaTHNaC. Typhoid fever. <https://travelhealthpro.org.uk/disease/184/typhoid-fever>. [Accessed 17 October 2019].
- [109] Gayet R, Bioley G, Rochereau N, Paul S, Corthesy B. Vaccination against Salmonella infection: the mucosal way. *Microbiol Mol Biol Rev* 2017;81(3). <https://doi.org/10.1128/mbr.00007-17>.
- [110] Germanier R, Fuer E. Isolation and characterization of Gal E mutant Ty 21a of Salmonella typhi: a candidate strain for a live, oral typhoid vaccine. *J Infect Dis* 1975;131(5):553–8. <https://doi.org/10.1093/infdis/131.5.553>.
- [111] Amicizia D, Arata L, Zangrillo F, Panatto D, Gasparini R. Overview of the impact of typhoid and paratyphoid fever. Utility of Ty21a vaccine (Vivotif®). *J Prev Med Hyg* 2017;58(1):E1–8.
- [112] Levine MM. Typhoid fever vaccines. In: Plotkin SA, Offit PA, Orenstein WA, Edwards KM, editors. *Plotkin's vaccines, 7th Edition*. Elsevier; 2018.
- [113] Black R, Levine MM, Young C, Rooney J, Levine S, Clements ML, et al. Immunogenicity of Ty21a attenuated "Salmonella typhi" given with sodium bicarbonate or in enteric-coated capsules. *Dev Biol Stand* 1983;53:9–14.
- [114] Forrest BD, LaBrooy JT, Beyer L, Dearlove CE, Shearman DJ. The human humoral immune response to Salmonella typhi Ty21a. *J Infect Dis* 1991;163(2):336–45. <https://doi.org/10.1093/infdis/163.2.336>.

- [115] D'Amelio R, Tagliabue A, Nencioni L, Di Addario A, Villa L, Manganaro M, et al. Comparative analysis of immunological responses to oral (Ty21a) and parenteral (TAB) typhoid vaccines. *Infect Immun* 1988;56(10):2731–5.
- [116] Nisini R, Biselli R, Matricardi PM, Fattorossi A, D'Amelio R. Clinical and immunological response to typhoid vaccination with parenteral or oral vaccines in two groups of 30 recruits. *Vaccine* 1993;11(5):582–6. [https://doi.org/10.1016/0264-410x\(93\)90237-r](https://doi.org/10.1016/0264-410x(93)90237-r).
- [117] Cancellieri V, Fara GM. Demonstration of specific IgA in human feces after immunization with live Ty21a Salmonella typhi vaccine. *J Infect Dis* 1985;151(3):482–4. <https://doi.org/10.1093/infdis/151.3.482>.
- [118] Kantele A, Kantele JM, Savilahti E, Westerholm M, Arvilommi H, Lazarovits A, et al. Homing potentials of circulating lymphocytes in humans depend on the site of activation: oral, but not parenteral, typhoid vaccination induces circulating antibody-secreting cells that all bear homing receptors directing them to the gut. *J Immunol* 1997;158(2):574–9.
- [119] Lahariya C. Vaccine epidemiology: a review. *J Fam Med Prim Care* 2016;5(1):7–15. <https://doi.org/10.4103/2249-4863.184616>.
- [120] Faucher JF, Binder R, Missinou MA, Matsiegui PB, Gruss H, Neubauer R, et al. Efficacy of atovaquone/proguanil for malaria prophylaxis in children and its effect on the immunogenicity of live oral typhoid and cholera vaccines. *Clin Infect Dis* 2002;35(10):1147–54. <https://doi.org/10.1086/342908>.
- [121] World Health Organization. HIV/AIDS Treatment and care: clinical protocols for the WHO European Region. [http://www.euro.who.int/\\_data/assets/pdf\\_file/0004/78106/E90840.pdf](http://www.euro.who.int/_data/assets/pdf_file/0004/78106/E90840.pdf). [Accessed 17 October 2019].
- [122] World Health Organization. Typhoid vaccines position paper 2018. [https://www.who.int/immunization/policy/position\\_papers/typhoid/en/](https://www.who.int/immunization/policy/position_papers/typhoid/en/). [Accessed 8 October 2019].
- [123] Griot-Wenk ME, Hartmann K, Herzog C, Ackermann J, Maspes B. Low rate of spontaneously reported adverse drug reactions in a recent post-marketing surveillance for Vivotif Berna. *Giorn Ital Med Trop* 2001;6(1).
- [124] Hu X, Chen Z, Xiong K, Wang J, Rao X, Cong Y. Vi capsular polysaccharide: synthesis, virulence, and application. *Crit Rev Microbiol* 2017;43(4):440–52. <https://doi.org/10.1080/1040841x.2016.1249335>.
- [125] Khan MI, Soofi SB, Ochiai RL, Habib MA, Sahito SM, Nizami SQ, et al. Effectiveness of Vi capsular polysaccharide typhoid vaccine among children: a cluster randomized trial in Karachi, Pakistan. *Vaccine* 2012;30(36):5389–95. <https://doi.org/10.1016/j.vaccine.2012.06.015>.
- [126] Michel R, Garnotel E, Spiegel A, Morillon M, Saliou P, Boutin JP. Outbreak of typhoid fever in vaccinated members of the French armed forces in the ivory coast. *Eur J Epidemiol* 2005;20(7):635–42. <https://doi.org/10.1007/s10654-005-7454-6>.
- [127] Poolman J, Borrow R. Hyporesponsiveness and its clinical implications after vaccination with polysaccharide or glycoconjugate vaccines. *Expert Rev Vaccines* 2011;10(3):307–22. <https://doi.org/10.1586/erv.11.8>.
- [128] Roggelin L, Vinnemeier CD, Fischer-Herr J, Johnson-Weaver BT, Rolling T, Burchard GD, et al. Serological response following re-vaccination with Salmonella typhi Vi-capsular polysaccharide vaccines in healthy adult travellers. *Vaccine* 2015;33(33):4141–5. <https://doi.org/10.1016/j.vaccine.2015.05.080>.
- [129] Kroon FP, van Dissel JT, Ravensbergen E, Nibbering PH, van Furth R. Impaired antibody response after immunization of HIV-infected individuals with the polysaccharide vaccine against Salmonella typhi (Typhim-Vi). *Vaccine* 1999;17(23–24):2941–5. [https://doi.org/10.1016/s0264-410x\(99\)00167-x](https://doi.org/10.1016/s0264-410x(99)00167-x).
- [130] Neuzil KM, Pollard AJ, Marfin AA. Introduction of typhoid conjugate vaccines in Africa and Asia. *Clin Infect Dis* 2019;68(Suppl 1):S27–30. <https://doi.org/10.1093/cid/ciy878>.
- [131] World Health Organization. Global Advisory Committee on Vaccine Safety, 30 November - 1 December 2016. *Wkly Epidemiol Rec* 2017;92(2):13–20.
- [132] Lin FY, Ho VA, Khien HB, Trach DD, Bay PV, Thanh TC, et al. The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children. *N Engl J Med* 2001;344(17):1263–9. <https://doi.org/10.1056/nejm200104263441701>.
- [133] Coalition against typhoid. Vaccines 2018. <https://www.coalitionagainsttyphoid.org/facts/prevention/vaccines/>. [Accessed 17 October 2019].
- [134] Bhutta ZA, Capeding MR, Bavdekar A, Marchetti E, Ariff S, Soofi SB, et al. Immunogenicity and safety of the Vi-CRM197 conjugate vaccine against typhoid fever in adults, children, and infants in south and southeast Asia: results from two randomised, observer-blind, age de-escalation, phase 2 trials. *Lancet Infect Dis* 2014;14(2):119–29. [https://doi.org/10.1016/s1473-3099\(13\)70241-x](https://doi.org/10.1016/s1473-3099(13)70241-x).
- [135] Goel A. Progress in the development of Vi-CRM197 conjugate vaccine. In: Paper presented at: 10<sup>th</sup> International Conference on Typhoid and Other Invasive Salmonellosis; 2017. Kampala, Uganda.
- [136] Clinicaltrials.gov. Safety, reactogenicity and immunogenicity of Vi-DT; typhoid conjugate vaccine. <https://clinicaltrials.gov/ct2/show/NCT03527355>. [Accessed 17 October 2019].
- [137] Clinicaltrials.gov. Immunogenicity and safety of Vi-DT (diphtheria toxoid) typhoid conjugate vaccine (Phase III). <https://clinicaltrials.gov/ct2/show/NCT04051268>. [Accessed 17 October 2019].
- [138] Medise BE, Soedjatmiko S, Rengganis I, Gunardi H, Sekartini R, Koesno S, et al. Six-month follow up of a randomized clinical trial-phase I study in Indonesian adults and children: safety and immunogenicity of Salmonella typhi polysaccharide-diphtheria toxoid (Vi-DT) conjugate vaccine. *PLoS One* 2019;14(2):e0211784. <https://doi.org/10.1371/journal.pone.0211784>.
- [139] Medise BE, Soedjatmiko S, Gunardi H, Sekartini R, Satari HI, Hadinegoro SR, et al. One-month follow up of a randomized clinical trial-phase II study in 6 to <24 months old Indonesian subjects: safety and immunogenicity of Vi-DT Typhoid Conjugate Vaccine. *Int J Infect Dis* 2020;93:102–7. <https://doi.org/10.1016/j.ijid.2020.01.045>.
- [140] Capeding MR, Sil A, Tadesse BT, Saluja T, Teshome S, Alberto E, et al. Safety and immunogenicity of Vi-DT conjugate vaccine among 6–23-month-old children: phase II, randomized, dose-scheduling, observer-blind study. *Eclinicalmedicine* 2020;27:100540. <https://doi.org/10.1016/j.eclim.2020.100540>.
- [141] Akinyemi KO, Oyefolu AOB, Mutiu WB, Iwalokun BA, Ayeni ES, Ajose SO, et al. Typhoid fever: tracking the trend in Nigeria. *Am J Trop Med Hyg* 2018;99(3\_Suppl):41–7. <https://doi.org/10.4269/ajtmh.18-0045>.
- [142] World Health Organization. Background paper to SAGE on typhoid vaccine policy. Recommendations 2017. [http://www.who.int/immunization/sage/meetings/2017/october/1\\_Typhoid\\_SAGE\\_background\\_paper\\_Final\\_v3B.pdf?ua=1](http://www.who.int/immunization/sage/meetings/2017/october/1_Typhoid_SAGE_background_paper_Final_v3B.pdf?ua=1). [Accessed 17 October 2019].
- [143] World Health Organization. Typhoid vaccine use in countries – progress and challenges: feedback from the regions and countries on the implementation of SAGE recommendations on typhoid vaccines. [https://www.who.int/immunization/sage/nov2010\\_report\\_typhoid\\_vaccines\\_namgyal.pdf](https://www.who.int/immunization/sage/nov2010_report_typhoid_vaccines_namgyal.pdf). [Accessed 8 October 2019].
- [144] Bentsi-Enchill AD, Hombach J. Revised global typhoid vaccination policy. *Clin Infect Dis* 2019;68(Suppl 1):S31–33. <https://doi.org/10.1093/cid/ciy927>.
- [145] Balaji V, Kapil A, Shastri J, Pragasam AK, Gole G, Choudhari S, et al. Longitudinal typhoid fever trends in India from 2000 to 2015. *Am J Trop Med Hyg* 2018;99(3\_Suppl):34–40. <https://doi.org/10.4269/ajtmh.18-0139>.
- [146] Maurice J. A first step in bringing typhoid fever out of the closet. *Lancet* 2012;379(9817):699–700. [https://doi.org/10.1016/s0140-6736\(12\)60294-3](https://doi.org/10.1016/s0140-6736(12)60294-3).
- [147] Gavi the Vaccine Alliance. Typhoid vaccine: Gavi's response. <https://www.gavi.org/support/nvs/typhoid/>. [Accessed 17 October 2019].
- [148] Breiman RF, Cosmas L, Njuguna H, Audi A, Olack B, Ochieng JB, et al. Population-based incidence of typhoid fever in an urban informal settlement and a rural area in Kenya: implications for typhoid vaccine use in Africa. *PLoS One* 2012;7(1):e29119. <https://doi.org/10.1371/journal.pone.0029119>.
- [149] Meiring JE, Laurens MB, Patel P, Patel P, Misiri T, Simiyu K, et al. Typhoid Vaccine Acceleration Consortium Malawi: a Phase III, randomized, double-blind, controlled trial of the clinical efficacy of typhoid conjugate vaccine among children in Blantyre, Malawi. *Clin Infect Dis* 2019;68(Suppl 2):S50–58. <https://doi.org/10.1093/cid/ciy1103>.
- [150] Lo NC, Gupta R, Stanaway JD, Garrett DO, Bogoch, Luby SP, et al. Comparison of strategies and incidence thresholds for Vi conjugate vaccines against typhoid fever: a cost-effectiveness modeling study. *J Infect Dis* 2018;218(Suppl 4):S232–242. <https://doi.org/10.1093/infdis/jix598>.
- [151] Cook J, Jeuland M, Whittington D, Poulos C, Clemens J, Sur D, et al. The cost-effectiveness of typhoid Vi vaccination programs: calculations for four urban sites in four Asian countries. *Vaccine* 2008;26(50):6305–16. <https://doi.org/10.1016/j.vaccine.2008.09.040>.
- [152] Antillon M, Bilcke J, Paltiel AD, Pitzer VE. Cost-effectiveness analysis of typhoid conjugate vaccines in five endemic low- and middle-income settings. *Vaccine* 2017;35(27):3506–14. <https://doi.org/10.1016/j.vaccine.2017.05.001>.
- [153] Kaufhold S, Yaesoubi R, Pitzer VE. Predicting the impact of typhoid conjugate vaccines on antimicrobial resistance. *Clin Infect Dis* 2019;68(Suppl 2):S96–104. <https://doi.org/10.1093/cid/ciy1108>.
- [154] Pakkanen SH, Kantele JM, Savolainen LE, Rombo L, Kantele A. Specific and cross-reactive immune response to oral Salmonella typhi Ty21a and parenteral Vi capsular polysaccharide typhoid vaccines administered concomitantly. *Vaccine* 2015;33(3):451–8. <https://doi.org/10.1016/j.vaccine.2014.11.030>.
- [155] Bhutta ZA, Gaffey MF, Crump JA, Steele D, Breiman RF, Mintz ED, et al. Typhoid fever: way forward. *Am J Trop Med Hyg* 2018;99(3\_Suppl):89–96. <https://doi.org/10.4269/ajtmh.18-0111>.
- [156] Harris JB, LaRocque RC, Qadri F, Ryan ET, Calderwood SB. Cholera. *Lancet* 2012;379(9835):2466–76. [https://doi.org/10.1016/s0140-6736\(12\)60436-x](https://doi.org/10.1016/s0140-6736(12)60436-x).
- [157] Hsiao A, Desai SN, Mogaale V, Excler JL, Digilio L. Lessons learnt from 12 oral cholera vaccine campaigns in resource-poor settings. *Bull World Health Organ* 2017;95(4):303–12. <https://doi.org/10.2471/blt.16.175166>.
- [158] M'Bangombe M, Pezzoli L, Reeder B, Kabuluzi S, Msyamboza K, Masuku H, et al. Oral cholera vaccine in cholera prevention and control, Malawi. *Bull World Health Organ* 2018;96(6):428–35. <https://doi.org/10.2471/blt.17.207175>.
- [159] Dellepiane N, Wood D. Twenty-five years of the WHO vaccines prequalification programme (1987–2012): lessons learned and future perspectives. *Vaccine* 2015;33(1):52–61. <https://doi.org/10.1016/j.vaccine.2013.11.066>.
- [160] Gavi the Vaccine Alliance. Millions of children set to be protected against typhoid fever. <https://www.gavi.org/library/news/press-releases/2017/millions-of-children-set-to-be-protected-against-typhoid-fever/>. [Accessed 17 October 2019].
- [161] Gavi the Vaccine Alliance. Eligibility 2019. <https://www.gavi.org/support/sustainability/eligibility/>. [Accessed 17 October 2019].
- [162] Mogaale V, Ramani E, Park IY, Lee JS. A forecast of typhoid conjugate vaccine introduction and demand in typhoid endemic low- and middle-income countries to support vaccine introduction policy and decisions. *Hum Vaccines Immunother* 2017;13(9):2017–24. <https://doi.org/10.1080/21645515.2017.1333681>.
- [163] Lindsay S, Gellin B, Lee A, Garrett D. The Coalition against Typhoid: mobilizing a community for a global fight. *Clin Infect Dis* 2019;68(Suppl 2):S161–164. <https://doi.org/10.1093/cid/ciy1117>.
- [164] University of Maryland School of Medicine. Typhoid vaccine acceleration Consortium. <http://www.medschool.umaryland.edu/CVD/TyVAC/>. [Accessed 8 October 2019].
- [165] Vilkmann K, Laaveri T, Pakkanen SH, Kantele A. Stand-by antibiotics encourage unwarranted use of antibiotics for travelers' diarrhea: a prospective study. *Trav Med Infect Dis* 2019;27:64–71. <https://doi.org/10.1016/j.tmaid.2018.06.007>.

- [166] Mahon BE, Newton AE, Mintz ED. Effectiveness of typhoid vaccination in US travelers. *Vaccine* 2014;32(29):3577–9. <https://doi.org/10.1016/j.vaccine.2014.04.055>.
- [167] Wagner KS, Freedman JL, Andrews NJ, Jones JA. Effectiveness of the typhoid Vi vaccine in overseas travelers from England. *J Trav Med* 2015;22(2):87–93. <https://doi.org/10.1111/jtm.12178>.
- [168] Greenaway C, Schofield S, Henteleff A, Plourde P, Geduld J, Abdel-Motagally M, et al. Summary of the statement on international travellers and typhoid by the Committee to Advise on Tropical Medicine and Travel (CATMAT). *Can Comm Dis Rep* 2014;40(4):60–70. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5864451/>.
- [169] NaTHNaC. Country specific information - rationale (Typhoid). <https://travelhealthpro.org.uk/factsheet/11/country-specific-information-rationale>. [Accessed 17 October 2019].
- [170] Jackson BR, Iqbal S, Mahon B. Updated recommendations for the use of typhoid vaccine—Advisory Committee on Immunization Practices, United States, 2015. *MMWR Morb Mortal Wkly Rep* 2015;64(11):305–8.
- [171] Australian Government: Department of Health. Australian immunisation handbook. <https://immunisationhandbook.health.gov.au>. [Accessed 15 October 2019].
- [172] Government of Canada. Homepage - travel section. <https://travel.gc.ca/destinations>. [Accessed 15 October 2019].
- [173] Institut Pasteur. Homepage - travel section. <https://www.pasteur.fr/fr/centre-medical/preparer-son-voyage>. [Accessed 15 October 2019].
- [174] Fit for Travel - travel medical information service. Homepage - travel section. <https://www.fit-for-travel.de/%C3%BCber-300-reiseziele/>. [Accessed 15 October 2019].
- [175] Paul Ehrlich Institute. Federal Institute for Vaccines and Biomedical Drugs. Notice No. 460 on the authorization of vaccines and biomedical medicines and other official acts (July 2019), [https://www.bundesanzeiger.de/ebanzwww/wexservlet?page.navid=to\\_bookmark\\_official&bookmark\\_id=zybsuLTUjG3zx0MPZ](https://www.bundesanzeiger.de/ebanzwww/wexservlet?page.navid=to_bookmark_official&bookmark_id=zybsuLTUjG3zx0MPZ). [Accessed 15 October 2019].
- [176] Sociedade Portuguesa De Medicina Do Viajante. Recomendacoes vacinas. [http://spm.simposium.pt/media/13961/Recomendacoes\\_Vacinas\\_SPMV\\_Ed01-2018.pdf](http://spm.simposium.pt/media/13961/Recomendacoes_Vacinas_SPMV_Ed01-2018.pdf). [Accessed 15 October 2019].
- [177] Sociedade Portuguesa De Medicina Do Viajante. Homepage - travel section. <http://spm.simposium.pt/destinos-frequentes/>. [Accessed 15 October 2019].
- [178] Tropical Medicine Bureau. Homepage. <https://www.tmb.ie>. [Accessed 15 October 2019].
- [179] Medicines.ie. Homepage. <https://www.medicines.ie/>. [Accessed 15 October 2019].
- [180] Fundación IO. Homepage - travel section. <http://fundacionio.org/viajar/paises.html>. [Accessed 15 October 2019].
- [181] Asociación Española de Vacunología. Homepage - travel section. <https://www.vacunas.org/vacunas-para-el-viajero/>. [Accessed 16 October 2019].
- [182] Safetravel.ch. Homepage. <http://www.safetravel.ch/safetravel2/servlet/ch.ofac.wv.wv201j.pages.Wv201AccueilCtrl?action=init>. [Accessed 7 October 2019].
- [183] Office Fédéral de la Santé Publique. OFSP - bulletin 50. Published 2018, [https://www.bag.admin.ch/dam/bag/fr/dokumente/cc/Kampagnen/Bulletin/2018/BU\\_50\\_18.pdf.download.pdf/BU\\_50\\_18\\_FR.pdf](https://www.bag.admin.ch/dam/bag/fr/dokumente/cc/Kampagnen/Bulletin/2018/BU_50_18.pdf.download.pdf/BU_50_18_FR.pdf). [Accessed 15 October 2019].
- [184] Homepage. Published 2019, <https://www.ggdreisvaccinaties.nl/heb-ik-een-vaccinatie-nodig>. [Accessed 15 October 2019].
- [185] NaTHNaC. Homepage - travel section. Published 2019, <https://travelhealthpro.org.uk/countries>. [Accessed 15 October 2019].
- [186] Public Health England. The green book of immunisation against infectious diseases - chapter 33 - Typhoid. [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment\\_data/file/809589/Greenbook\\_chapter\\_33\\_Typhoid\\_May\\_2019.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/809589/Greenbook_chapter_33_Typhoid_May_2019.pdf). [Accessed 15 October 2019].
- [187] Centers for Disease Control and Prevention. Homepage - travel section. <https://wwwnc.cdc.gov/travel/>. [Accessed 15 October 2019].
- [188] Health GSoTMaG. Recommendations and guidelines: typhoid. Published 2020, <https://www.dtg.org/index.php/empfehlungen-und-leitlinien/empfehlungen/impfungen/impfrisiko-aufklaerung/uebersicht-der-reiseimpfungen/249-typhus.html>. [Accessed 20 November 2020].
- [189] Coalition against Typhoid. Typhoid and safe water, sanitation and hygiene. <http://www.coalitionagainststtyphoid.org/prevent-treat/typhoid-and-wash/>. [Accessed 10 October 2019].